Drug-patents-expiring-in-2029
1. Abilify Mycite Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8956288 | OTSUKA | In-body power source having high surface area electrode |
Jul, 2029
(3 years from now) | |
| US8674825 | OTSUKA | Pharma-informatics system |
Apr, 2029
(3 years from now) | |
| US8945005 | OTSUKA | Controlled activation ingestible identifier |
Aug, 2029
(3 years from now) | |
| US9149577 | OTSUKA | Body-associated receiver and method |
Dec, 2029
(4 years from now) | |
| US10441194 | OTSUKA | Ingestible event marker systems |
Jul, 2029
(3 years from now) | |
| US9433371 | OTSUKA | In-body device with virtual dipole signal amplification |
Sep, 2029
(4 years from now) | |
| US8718193 | OTSUKA | Active signal processing personal health signal receivers |
Dec, 2029
(4 years from now) | |
| US9060708 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(3 years from now) | |
| US9258035 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver; Method of using a receiver to receive a signal from a tablet emb...
Dosage: TABLET
More Information on Dosage
ABILIFY MYCITE KIT family patents
2. Acanya patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8288434 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Aug, 2029
(3 years from now) | |
| US8895070 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(3 years from now) | |
| US10220049 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(3 years from now) | |
| US10624918 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(3 years from now) | |
| US8663699 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(3 years from now) | |
| US9078870 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(3 years from now) | |
Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 23 October, 2008
Treatment: Treatment of acne; Topical treatment of acne vulgaris in patients 12 years or older
Dosage: GEL
How can I launch a generic of ACANYA before it's drug patent expiration?
More Information on Dosage
ACANYA family patents
3. Actoplus Met patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9320714 | TAKEDA PHARMS USA | Tablet |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-116) | May 17, 2015 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 August, 2005
Treatment: NA
Dosage: TABLET
More Information on Dosage
ACTOPLUS MET family patents
4. Acuvail patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7842714 | ABBVIE | Ketorolac tromethamine compositions for treating ocular pain |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 22, 2012 |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS
How can I launch a generic of ACUVAIL before it's drug patent expiration?
More Information on Dosage
ACUVAIL family patents
5. Adlyxin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9855388 | SANOFI-AVENTIS US | Dosing and drive mechanism for drug delivery device |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 27 July, 2016
Treatment: Improvement in glycemic control in type 2 diabetes mellitus patients by use of a pen injector
Dosage: SOLUTION
More Information on Dosage
ADLYXIN family patents
6. Afrezza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10342938 | MANNKIND | Dry powder drug delivery system |
Jun, 2029
(3 years from now) | |
| US9339615 | MANNKIND | Dry powder inhaler and system for drug delivery |
Oct, 2029
(4 years from now) | |
| US9943571 | MANNKIND | Use of ultrarapid acting insulin |
Aug, 2029
(3 years from now) | |
| US8912193 | MANNKIND | Dry powder inhaler and system for drug delivery |
Jun, 2029
(3 years from now) | |
| US8623817 | MANNKIND | Method of treating diabetes type 2 by administering ultrarapid acting insulin |
Sep, 2029
(4 years from now) | |
| US9446133 | MANNKIND | Dry powder inhaler and system for drug delivery |
Jun, 2029
(3 years from now) | |
| US8119593 | MANNKIND | Method of treating diabetes type 2 by metformin and an ultrarapid acting insulin |
Aug, 2029
(3 years from now) | |
| US9192675 | MANNKIND | Dry powder inhaler and system for drug delivery |
Jun, 2029
(3 years from now) | |
| US8258095 | MANNKIND | Method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content |
Aug, 2029
(3 years from now) | |
| US9393372 | MANNKIND | Dry powder drug delivery system |
Jul, 2029
(3 years from now) | |
| US10046031 | MANNKIND | Use of ultrarapid acting insulin |
Aug, 2029
(3 years from now) | |
| US9662461 | MANNKIND | Dry powder drug delivery system and methods |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 27, 2017 |
Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient
Market Authorisation Date: 27 June, 2014
Treatment: Treatment of a patient having diabetes mellitus with a prandial rapid acting insulin.; Administration of fdkp microparticles comprising insulin.; Use of an inhaler to administer dry powder medicament;...
Dosage: POWDER
More Information on Dosage
AFREZZA family patents
7. Agamree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857161 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-kB for treatment of disease |
May, 2029
(3 years from now) | |
| US8334279 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-κB for treatment of disease |
May, 2029
(3 years from now) | |
| US11833159 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-kB for treatment of disease |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2028 |
| Orphan Drug Exclusivity(ODE-450) | Oct 26, 2030 |
Drugs and Companies using VAMOROLONE ingredient
NCE-1 date: 27 October, 2027
Market Authorisation Date: 26 October, 2023
Treatment: Treatment of duchenne muscular dystrophy
Dosage: SUSPENSION
More Information on Dosage
AGAMREE family patents
8. Akeega patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8436185 | JANSSEN BIOTECH | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 11, 2026 |
Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 11 August, 2023
Treatment: NA
Dosage: TABLET
More Information on Dosage
AKEEGA family patents
9. Aliqopa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8466283 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Oct, 2029
(4 years from now) | |
| USRE46856 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 14, 2022 |
| Orphan Drug Exclusivity(ODE) | Sep 14, 2024 |
| Orphan Drug Exclusivity(ODE-155) | Sep 14, 2024 |
Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient
NCE-1 date: 14 September, 2021
Market Authorisation Date: 14 September, 2017
Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
Dosage: POWDER
More Information on Dosage
ALIQOPA family patents
10. Alunbrig patent expiration
ALUNBRIG's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9273077 | TAKEDA PHARMS USA | Phosphorus derivatives as kinase inhibitors |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| New Indication(I-847) | May 22, 2023 |
| Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-142) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-300) | May 22, 2027 |
Drugs and Companies using BRIGATINIB ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
Dosage: TABLET
More Information on Dosage
ALUNBRIG family patents
11. Alyftrek patent expiration
ALYFTREK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2029 |
Drugs and Companies using DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM ingredient
NCE-1 date: 20 December, 2028
Market Authorisation Date: 20 December, 2024
Treatment: Treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation or another responsive mutation in the cftr gene with a composition according to claim 1 of us1156...
Dosage: TABLET
More Information on Dosage
ALYFTREK family patents
12. Amondys 45 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE48960 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2026 |
| Orphan Drug Exclusivity(ODE-347) | Feb 25, 2028 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 25 February, 2025
Market Authorisation Date: 25 February, 2021
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping
Dosage: SOLUTION
More Information on Dosage
AMONDYS 45 family patents
13. Amvuttra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 13, 2027 |
| New Indication(I-964) | Mar 20, 2028 |
| Orphan Drug Exclusivity(ODE-212) | Jun 13, 2029 |
Drugs and Companies using VUTRISIRAN SODIUM ingredient
NCE-1 date: 13 June, 2026
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION
More Information on Dosage
AMVUTTRA family patents
14. Angiomax patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7582727 (Pediatric) | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(3 years from now) | |
|
US7598343 (Pediatric) | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(3 years from now) | |
Drugs and Companies using BIVALIRUDIN ingredient
Market Authorisation Date: 15 December, 2000
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of ANGIOMAX before it's drug patent expiration?
More Information on Dosage
ANGIOMAX family patents
15. Anoro Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2016 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: NA
Dosage: POWDER
More Information on Dosage
ANORO ELLIPTA family patents
16. Arnuity Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 20, 2017 |
| New Patient Population(NPP) | May 17, 2021 |
| New Strength(NS) | May 17, 2021 |
| M(M-290) | Mar 01, 2026 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARNUITY ELLIPTA family patents
17. Atripla patent expiration
ATRIPLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8598185 | GILEAD SCIENCES | Unitary pharmaceutical dosage form |
Apr, 2029
(3 years from now) | |
Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 12 July, 2006
Treatment: NA
Dosage: TABLET
How can I launch a generic of ATRIPLA before it's drug patent expiration?
More Information on Dosage
ATRIPLA family patents
18. Auvi-q patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8226610 | KALEO INC | Medical injector with compliance tracking and monitoring |
Apr, 2029
(3 years from now) | |
| US8021344 | KALEO INC | Medicament delivery device configured to produce an audible output |
Nov, 2029
(4 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 17 November, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
AUVI-Q family patents
19. Avmapki Fakzynja Co-pack (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7928109 | VERASTEM INC | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2030 |
Drugs and Companies using AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE ingredient
NCE-1 date: 08 May, 2029
Market Authorisation Date: 08 May, 2025
Treatment: NA
Dosage: CAPSULE, TABLET
More Information on Dosage
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) family patents
20. Baxdela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8497378 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(4 years from now) | |
| US8871938 | MELINTA | Process for making quinolone compounds |
Sep, 2029
(4 years from now) | |
| USRE46617 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9200088 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9750822 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US7635773 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
| New Indication(I-815) | Oct 24, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 19 June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: NA
Dosage: POWDER; TABLET
More Information on Dosage
BAXDELA family patents
21. Belsomra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7951797 | MERCK SHARP DOHME | Substituted diazepan orexin receptor antagonists |
Nov, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2019 |
| M(M-253) | Jan 29, 2023 |
Drugs and Companies using SUVOREXANT ingredient
NCE-1 date: 13 August, 2018
Market Authorisation Date: 13 August, 2014
Treatment: Treatment of insomnia
Dosage: TABLET
More Information on Dosage
BELSOMRA family patents
22. Belviq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168624 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 27 June, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of BELVIQ before it's drug patent expiration?
More Information on Dosage
BELVIQ family patents
23. Belviq Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8168624 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 15 July, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of BELVIQ XR before it's drug patent expiration?
More Information on Dosage
BELVIQ XR family patents
24. Besivance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8937062 | BAUSCH AND LOMB | Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria |
Nov, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2014 |
Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient
NCE-1 date: 28 May, 2013
Market Authorisation Date: 28 May, 2009
Treatment: Method of treating ocular bacterial infections
Dosage: SUSPENSION/DROPS
More Information on Dosage
BESIVANCE family patents
25. Blujepa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8389524 | GLAXOSMITHKLINE | Tricyclic nitrogen containing compounds as antibacterial agents |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 25, 2035 |
Drugs and Companies using GEPOTIDACIN MESYLATE ingredient
NCE-1 date: 25 March, 2034
Market Authorisation Date: 25 March, 2025
Treatment: Treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kg with uncomplicated urinary tract infections (uuti) caused by escherichia coli, klebsiella pneumoniae,...
Dosage: TABLET
More Information on Dosage
BLUJEPA family patents
26. Braftovi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8946250 | ARRAY BIOPHARMA INC | 3,4-diarylpyrazoles as protein kinase inhibitors |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-826) | Apr 08, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
| New Indication(I-957) | Dec 20, 2027 |
| Orphan Drug Exclusivity(ODE-445) | Oct 11, 2030 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage
BRAFTOVI family patents
27. Brenzavvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7838499 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Jan, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 20 January, 2027
Market Authorisation Date: 20 January, 2023
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET
More Information on Dosage
BRENZAVVY family patents
28. Breo Ellipta patent expiration
BREO ELLIPTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11116721 | GLAXO GRP LTD | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Feb, 2029
(3 years from now) | |
|
US11116721 (Pediatric) | GLAXO GRP LTD | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 30, 2018 |
| New Indication(I-708) | Apr 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | May 10, 2018 |
| M(M-202) | May 15, 2020 |
| New Patient Population(NPP) | May 13, 2026 |
| New Strength(NS) | May 13, 2026 |
| Pediatric Exclusivity(PED) | Nov 13, 2026 |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 13 November, 2025
Market Authorisation Date: 12 May, 2023
Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older
Dosage: POWDER
More Information on Dosage
BREO ELLIPTA family patents
29. Brisdelle patent expiration
BRISDELLE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8658663 | LEGACY PHARMA | Method of treating thermoregulatory disfunction with paroxetine |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2016 |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 28 June, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: CAPSULE
How can I launch a generic of BRISDELLE before it's drug patent expiration?
More Information on Dosage
BRISDELLE family patents
30. Bromsite patent expiration
Can you believe BROMSITE received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778999 | SUN PHARM | Non-steroidal anti-inflammatory ophthalmic compositions |
Aug, 2029
(3 years from now) | |
| USRE50218 | SUN PHARM | Non-steroidal anti-inflammatory ophthalmic compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 08, 2019 |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 08 April, 2016
Treatment: Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery
Dosage: SOLUTION/DROPS
How can I launch a generic of BROMSITE before it's drug patent expiration?
More Information on Dosage
BROMSITE family patents
31. Bydureon patent expiration
BYDUREON's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2015 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON family patents
32. Bydureon Pen patent expiration
BYDUREON PEN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8690837 | ASTRAZENECA AB | Mixing device for a two-chamber ampoule |
May, 2029
(3 years from now) | |
| US8827963 | ASTRAZENECA AB | Administering device with holding mechanism |
Feb, 2029
(3 years from now) | |
|
US8690837 (Pediatric) | ASTRAZENECA AB | Mixing device for a two-chamber ampoule |
Nov, 2029
(4 years from now) | |
|
US8827963 (Pediatric) | ASTRAZENECA AB | Administering device with holding mechanism |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON PEN family patents
33. Cabtreo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10624918 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(3 years from now) | |
| US10220049 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(3 years from now) | |
| US9561208 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(3 years from now) | |
| US8288434 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2026 |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 20 October, 2023
Treatment: Topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older
Dosage: GEL
More Information on Dosage
CABTREO family patents
34. Caldolor patent expiration
CALDOLOR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9295639 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(4 years from now) | |
| US9114068 | CUMBERLAND PHARMS | Treating patients with intravenous ibuprofen |
Sep, 2029
(4 years from now) | |
| US8735452 | CUMBERLAND PHARMS | Treating patients with intravenous ibuprofen |
Sep, 2029
(4 years from now) | |
| US9649284 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(4 years from now) | |
| US8871810 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(4 years from now) | |
| US9138404 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 11, 2012 |
| New Dosing Schedule(D-152) | Nov 20, 2018 |
| M(M-128) | Nov 19, 2024 |
| New Patient Population(NPP) | May 11, 2026 |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 11 June, 2009
Treatment: Methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation and/or fever with intravenous ibuprof...
Dosage: SOLUTION
More Information on Dosage
CALDOLOR family patents
35. Caplyta patent expiration
Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8648077 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
Dec, 2029
(4 years from now) | |
| USRE48825 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
Mar, 2029
(3 years from now) | |
| US9586960 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8598119 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
Dec, 2029
(4 years from now) | |
| US9199995 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
Mar, 2029
(3 years from now) | |
| US10117867 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(3 years from now) | |
| US9616061 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(3 years from now) | |
| US9168258 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-882) | Dec 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: Treatment of schizophrenia; Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression
Dosage: CAPSULE
More Information on Dosage
CAPLYTA family patents
36. Carnexiv patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7635773 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9750822 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 07, 2023 |
| Orphan Drug Exclusivity(ODE-124) | Oct 07, 2023 |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 07 October, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
CARNEXIV family patents
37. Colcrys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440722 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(3 years from now) | |
| US7601758 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares |
Feb, 2029
(3 years from now) | |
| US7906519 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(3 years from now) | |
| US8440721 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(3 years from now) | |
| US7820681 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(3 years from now) | |
| US7915269 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-603) | Jul 30, 2012 |
| Orphan Drug Exclusivity(ODE) | Jul 29, 2016 |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 29 July, 2009
Treatment: Method of using colchicine for the prophylaxis of gout flares; Method of treating gout flares; Method of administering colchicine to familial mediterranean fever patients
Dosage: TABLET
How can I launch a generic of COLCRYS before it's drug patent expiration?
More Information on Dosage
COLCRYS family patents
38. Consensi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9662315 | PURPLE BIOTECH | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 31, 2021 |
Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate
Dosage: TABLET
How can I launch a generic of CONSENSI before it's drug patent expiration?
More Information on Dosage
CONSENSI family patents
39. Contrave patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11324741 | NALPROPION | Methods for treating visceral fat conditions |
May, 2029
(3 years from now) | |
| US8088786 | NALPROPION | Layered pharmaceutical formulations |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage
CONTRAVE family patents
40. Copiktra patent expiration
Can you believe COPIKTRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216982 | SECURA | Certain chemical entities, compositions and methods |
Jan, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2023 |
| Orphan Drug Exclusivity(ODE-208) | Sep 24, 2025 |
| Orphan Drug Exclusivity(ODE-209) | Sep 24, 2025 |
Drugs and Companies using DUVELISIB ingredient
NCE-1 date: 24 September, 2022
Market Authorisation Date: 24 September, 2018
Treatment: For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)
Dosage: CAPSULE
More Information on Dosage
COPIKTRA family patents
41. Cotellic patent expiration
COTELLIC's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7803839 | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Nov, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 10, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 10, 2022 |
| Orphan Drug Exclusivity(ODE-101) | Nov 10, 2022 |
| M(M-278) | Jul 28, 2025 |
| New Indication(I-902) | Oct 28, 2025 |
| Pediatric Exclusivity(PED) | Jan 28, 2026 |
| Orphan Drug Exclusivity(ODE-416) | Oct 28, 2029 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
NCE-1 date: 28 January, 2025
Market Authorisation Date: 10 November, 2015
Treatment: NA
Dosage: TABLET
More Information on Dosage
COTELLIC family patents
42. Daklinza patent expiration
DAKLINZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8329159 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-161) | Feb 05, 2019 |
| New Dosing Schedule(D-162) | Feb 05, 2019 |
| New Indication(I-726) | Feb 05, 2019 |
| New Indication(I-727) | Feb 05, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2020 |
Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient
NCE-1 date: 25 July, 2019
Market Authorisation Date: 24 July, 2015
Treatment: NA
Dosage: TABLET
More Information on Dosage
DAKLINZA family patents
43. Desyrel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8133893 | PRAGMA | Trazodone and trazodone hydrochloride in purified form |
Mar, 2029
(3 years from now) | |
Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 01 January, 1982
Treatment: NA
Dosage: TABLET
How can I launch a generic of DESYREL before it's drug patent expiration?
More Information on Dosage
DESYREL family patents
44. Dexilant Solutab patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9241910 | TAKEDA PHARMS USA | Orally-disintegrating solid preparation |
Mar, 2029
(3 years from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
More Information on Dosage
DEXILANT SOLUTAB family patents
45. Dojolvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8697748 | ULTRAGENYX PHARM INC | Glycogen or polysaccharide storage disease treatment method |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 30, 2025 |
| Orphan Drug Exclusivity(ODE-311) | Jun 30, 2027 |
Drugs and Companies using TRIHEPTANOIN ingredient
NCE-1 date: 30 June, 2024
Market Authorisation Date: 30 June, 2020
Treatment: NA
Dosage: LIQUID
More Information on Dosage
DOJOLVI family patents
46. Dovato patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 08, 2022 |
| New Indication(I-839) | Aug 06, 2023 |
| New Patient Population(NPP) | Apr 05, 2027 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 08 April, 2019
Treatment: NA
Dosage: TABLET
How can I launch a generic of DOVATO before it's drug patent expiration?
More Information on Dosage
DOVATO family patents
47. Duaklir Pressair patent expiration
DUAKLIR PRESSAIR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10085974 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
| US11000517 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)
Dosage: POWDER, METERED
More Information on Dosage
DUAKLIR PRESSAIR family patents
48. Durysta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7799336 | ABBVIE | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: NA
Dosage: IMPLANT
More Information on Dosage
DURYSTA family patents
49. Dutrebis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7754731 | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7754731 (Pediatric) | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(4 years from now) | |
Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 06 February, 2015
Treatment: Treatment of hiv-1 infection
Dosage: TABLET
More Information on Dosage
DUTREBIS family patents
50. Duzallo patent expiration
Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8084483 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Aug, 2029
(3 years from now) | |
| US8546437 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Apr, 2029
(3 years from now) | |
| US8357713 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Dec, 2029
(4 years from now) | |
Drugs and Companies using ALLOPURINOL; LESINURAD ingredient
Market Authorisation Date: 18 August, 2017
Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone
Dosage: TABLET
More Information on Dosage
DUZALLO family patents
51. Dyanavel Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8062667 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 19, 2018 |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 19 October, 2015
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
DYANAVEL XR family patents
52. Ella patent expiration
ELLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735380 | LAB HRA PHARMA | Ulipristal acetate tablets |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2015 |
| M(M-271) | Jun 24, 2024 |
Drugs and Companies using ULIPRISTAL ACETATE ingredient
NCE-1 date: 13 August, 2014
Market Authorisation Date: 13 August, 2010
Treatment: NA
Dosage: TABLET
How can I launch a generic of ELLA before it's drug patent expiration?
More Information on Dosage
ELLA family patents
53. Embeda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623418 | ALPHARMA PHARMS | Pharmaceutical composition |
Nov, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 13, 2012 |
Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 August, 2009
Treatment: Treatment of moderate to severe chronic pain by administering an intact composition as claimed
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of EMBEDA before it's drug patent expiration?
More Information on Dosage
EMBEDA family patents
54. Ensacove patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9296724 | XCOVERY | Substituted pyridazinecarboxamides as kinase inhibitors |
Jun, 2029
(3 years from now) | |
| US8551995 | XCOVERY | Kinase inhibitor compounds |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2029 |
Drugs and Companies using ENSARTINIB HYDROCHLORIDE ingredient
NCE-1 date: 18 December, 2028
Market Authorisation Date: 18 December, 2024
Treatment: Treatment of adult patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc) who have not previously received an alk-inhibitor
Dosage: CAPSULE
More Information on Dosage
ENSACOVE family patents
55. Entereg patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8645160 | CUBIST PHARMS | Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2013 |
| M(M-128) | Oct 18, 2016 |
Drugs and Companies using ALVIMOPAN ingredient
NCE-1 date: 20 May, 2012
Market Authorisation Date: 20 May, 2008
Treatment: Treating a subject undergoing abdominal surgery by administering alvimopan to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection ...
Dosage: CAPSULE
How can I launch a generic of ENTEREG before it's drug patent expiration?
More Information on Dosage
ENTEREG family patents
56. Eohilia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324192 | TAKEDA PHARMS USA | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
Aug, 2029
(3 years from now) | |
| US9050368 | TAKEDA PHARMS USA | Corticosteroid compositions |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 09, 2027 |
| Orphan Drug Exclusivity(ODE-466) | Feb 09, 2031 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 09 February, 2024
Treatment: Treatment of eosinophilic esophagitis
Dosage: SUSPENSION
More Information on Dosage
EOHILIA family patents
57. Epclusa patent expiration
EPCLUSA's oppositions filed in EPO
EPCLUSA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(3 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(4 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2021 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| New Patient Population(NPP) | Mar 19, 2023 |
| New Strength(NS) | Mar 19, 2023 |
| M(M-264) | Jul 14, 2023 |
| M(M-277) | Apr 27, 2025 |
| ODE*(ODE*) | Mar 19, 2027 |
| Orphan Drug Exclusivity(ODE-293) | Mar 19, 2027 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Market Authorisation Date: 10 June, 2021
Treatment: For the treatment of hepatitis c
Dosage: PELLETS; TABLET
More Information on Dosage
EPCLUSA family patents
58. Esbriet patent expiration
ESBRIET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8592462 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US7566729 | GENENTECH INC | Modifying pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US8609701 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US7635707 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: Dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits...
Dosage: CAPSULE; TABLET
How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage
ESBRIET family patents
59. Eucrisa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8039451 | ANACOR PHARMS INC | Boron-containing small molecules |
Jun, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8039451 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2021 |
| New Patient Population(NPP) | Mar 23, 2023 |
| Pediatric Exclusivity(PED) | Sep 23, 2023 |
| New Dosing Schedule(D-191) | Apr 03, 2026 |
Drugs and Companies using CRISABOROLE ingredient
NCE-1 date: 23 September, 2022
Market Authorisation Date: 14 December, 2016
Treatment: NA
Dosage: OINTMENT
How can I launch a generic of EUCRISA before it's drug patent expiration?
More Information on Dosage
EUCRISA family patents
60. Evomela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9200088 | ACROTECH BIOPHARMA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | ACROTECH BIOPHARMA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Mar 10, 2023 |
| Orphan Drug Exclusivity(ODE-110) | Mar 10, 2023 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: NA
Dosage: POWDER
How can I launch a generic of EVOMELA before it's drug patent expiration?
More Information on Dosage
EVOMELA family patents
61. Evotaz patent expiration
EVOTAZ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148374 | BRISTOL | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 29 January, 2015
Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET
How can I launch a generic of EVOTAZ before it's drug patent expiration?
More Information on Dosage
EVOTAZ family patents
62. Evzio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8223610 | KALEO INC | Apparatus and method for initializing information recording medium, apparatus and method for recording information, and information recording medium |
Apr, 2029
(3 years from now) | |
| US8226610 | KALEO INC | Medical injector with compliance tracking and monitoring |
Apr, 2029
(3 years from now) | |
| US8021344 | KALEO INC | Medicament delivery device configured to produce an audible output |
Nov, 2029
(4 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO family patents
63. Evzio (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8021344 | KALEO INC | Medicament delivery device configured to produce an audible output |
Nov, 2029
(4 years from now) | |
| US8226610 | KALEO INC | Medical injector with compliance tracking and monitoring |
Apr, 2029
(3 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO (AUTOINJECTOR) family patents
64. Exondys 51 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47769 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Sep 19, 2023 |
| Orphan Drug Exclusivity(ODE-122) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
NCE-1 date: 19 September, 2020
Market Authorisation Date: 19 September, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EXONDYS 51 family patents
65. Farxiga patent expiration
FARXIGA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7851502 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-157) | Mar 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-212) | Oct 20, 2020 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Indication(I-834) | May 05, 2023 |
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage
FARXIGA family patents
66. Ferriprox patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8703156 | CHIESI | Liquid formulation for deferiprone with palatable taste |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 14, 2016 |
| Orphan Drug Exclusivity(ODE) | Oct 14, 2018 |
| Orphan Drug Exclusivity(ODE-16) | Oct 14, 2018 |
| New Indication(I-859) | Apr 30, 2024 |
| Orphan Drug Exclusivity(ODE-417) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-418) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-419) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-420) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-421) | Apr 30, 2028 |
Drugs and Companies using DEFERIPRONE ingredient
NCE-1 date: 15 October, 2015
Market Authorisation Date: 20 April, 2018
Treatment: Method of treating transfusional iron overload
Dosage: SOLUTION
How can I launch a generic of FERRIPROX before it's drug patent expiration?
More Information on Dosage
FERRIPROX family patents
67. Finacea patent expiration
FINACEA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9211259 | LEO PHARMA AS | Antibiotic kit and composition and uses thereof |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 29, 2018 |
Drugs and Companies using AZELAIC ACID ingredient
Market Authorisation Date: 29 July, 2015
Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea
Dosage: AEROSOL, FOAM
How can I launch a generic of FINACEA before it's drug patent expiration?
More Information on Dosage
FINACEA family patents
68. Firmagon patent expiration
FIRMAGON's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9579359 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Feb, 2029
(3 years from now) | |
| US10973870 | FERRING | Methods of treating prostate cancer with GnRH antagonist |
Feb, 2029
(3 years from now) | |
| US10729739 | FERRING | Methods of treating prostate cancer with GnRH antagonist |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 24, 2013 |
Drugs and Companies using DEGARELIX ACETATE ingredient
NCE-1 date: 24 December, 2012
Market Authorisation Date: 24 December, 2008
Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect
Dosage: POWDER
How can I launch a generic of FIRMAGON before it's drug patent expiration?
More Information on Dosage
FIRMAGON family patents
69. Fyarro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8911786 | AADI SUB | Nanoparticle comprising rapamycin and albumin as anticancer agent |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 22, 2024 |
| Orphan Drug Exclusivity(ODE-386) | Nov 22, 2028 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma)
Dosage: POWDER
More Information on Dosage
FYARRO family patents
70. Galafold patent expiration
Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8592362 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(3 years from now) | |
| US9095584 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(3 years from now) | |
| US10813921 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE
How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage
GALAFOLD family patents
71. Gelnique patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10449173 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(4 years from now) | |
| US9259388 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 27, 2012 |
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 27 January, 2009
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel; Treatment of overactive bladd...
Dosage: GEL
How can I launch a generic of GELNIQUE before it's drug patent expiration?
More Information on Dosage
GELNIQUE family patents
72. Gemtesa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8653260 | UROVANT | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2025 |
| New Indication(I-955) | Dec 18, 2027 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 23 December, 2024
Market Authorisation Date: 23 December, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
GEMTESA family patents
73. Genosyl patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9604028 | VERO BIOTECH INC | Systems and devices for generating nitric oxide |
Aug, 2029
(3 years from now) | |
| US8944049 | VERO BIOTECH INC | Systems and devices for generating nitric oxide |
Aug, 2029
(3 years from now) | |
| US10926054 | VERO BIOTECH INC | Systems and devices for generating nitric oxide |
Aug, 2029
(3 years from now) | |
| US11511252 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Sep, 2029
(4 years from now) | |
| US9701538 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Jan, 2029
(3 years from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: A method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia
Dosage: GAS
More Information on Dosage
GENOSYL family patents
74. Genvoya patent expiration
GENVOYA's oppositions filed in EPO
GENVOYA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148374 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9891239 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Dosing Schedule(D-173) | Dec 10, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET
How can I launch a generic of GENVOYA before it's drug patent expiration?
More Information on Dosage
GENVOYA family patents
75. Giapreza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9867863 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(4 years from now) | |
| US10335451 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(4 years from now) | |
| US10548943 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(4 years from now) | |
| US10500247 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2022 |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
NCE-1 date: 21 December, 2021
Market Authorisation Date: 23 December, 2021
Treatment: Treating refractory hypotension with about 5 ng/kg/min to about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor; Treating hypotension with about 20 ng/kg/min to about 40 ng/kg/min angio...
Dosage: SOLUTION
How can I launch a generic of GIAPREZA before it's drug patent expiration?
More Information on Dosage
GIAPREZA family patents
76. Gilotrif patent expiration
GILOTRIF's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8426586 | BOEHRINGER INGELHEIM | Process for preparing amino crotonyl compounds |
Oct, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8545884 | BOEHRINGER INGELHEIM | Solid pharmaceutical formulations comprising BIBW 2992 |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 12, 2018 |
| New Indication(I-730) | Apr 15, 2019 |
| Orphan Drug Exclusivity(ODE-50) | Jul 12, 2020 |
| New Indication(I-763) | Jan 12, 2021 |
| Orphan Drug Exclusivity(ODE) | Apr 15, 2023 |
| Orphan Drug Exclusivity(ODE-115) | Apr 15, 2023 |
| Orphan Drug Exclusivity(ODE-230) | Jan 12, 2025 |
| M(M-276) | Apr 07, 2025 |
| Pediatric Exclusivity(PED) | Oct 07, 2025 |
Drugs and Companies using AFATINIB DIMALEATE ingredient
NCE-1 date: 07 October, 2024
Market Authorisation Date: 12 July, 2013
Treatment: NA
Dosage: TABLET
How can I launch a generic of GILOTRIF before it's drug patent expiration?
More Information on Dosage
GILOTRIF family patents
77. Gimoti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12194009 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(4 years from now) | |
| US12194008 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(4 years from now) | |
| US11020361 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(4 years from now) | |
| US11813231 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(4 years from now) | |
| US11628150 | EVOKE PHARMA INC | Nasal formulations of metoclopramide |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 19, 2023 |
Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 June, 2020
Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis
Dosage: SPRAY, METERED
How can I launch a generic of GIMOTI before it's drug patent expiration?
More Information on Dosage
GIMOTI family patents
78. Givlaari patent expiration
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION
More Information on Dosage
GIVLAARI family patents
79. Glyxambi patent expiration
GLYXAMBI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(4 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin
Dosage: TABLET
How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage
GLYXAMBI family patents
80. Harvoni patent expiration
HARVONI's oppositions filed in EPO
HARVONI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(3 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(4 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(4 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-153) | Nov 12, 2018 |
| New Indication(I-718) | Nov 12, 2018 |
| New Indication(I-719) | Nov 12, 2018 |
| New Indication(I-720) | Nov 12, 2018 |
| New Dosing Schedule(D-158) | Feb 12, 2019 |
| New Dosing Schedule(D-159) | Feb 12, 2019 |
| New Dosing Schedule(D-160) | Feb 12, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Patient Population(NPP) | Apr 07, 2020 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| Orphan Drug Exclusivity(ODE-136) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-262) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-263) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-264) | Aug 28, 2026 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: PELLETS; TABLET
More Information on Dosage
HARVONI family patents
81. Horizant patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8795725 | AZURITY | GABA analog prodrug sustained release oral dosage forms |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-652) | Jun 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 06, 2019 |
| Orphan Drug Exclusivity(ODE-25) | Jun 06, 2019 |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 13 December, 2011
Treatment: Management of postherpetic neuralgia (phn) in adults
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage
HORIZANT family patents
82. Ibsrela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8969377 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(4 years from now) | |
| US12016856 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9408840 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 12 September, 2019
Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor
Dosage: TABLET
More Information on Dosage
IBSRELA family patents
83. Inbrija patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE43711 | MERZ | Pulmonary delivery for levodopa |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 21, 2021 |
Drugs and Companies using LEVODOPA ingredient
Market Authorisation Date: 21 December, 2018
Treatment: Intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles
Dosage: POWDER
More Information on Dosage
INBRIJA family patents
84. Incruse Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8201556 | GLAXO GRP ENGLAND | Medicament dispenser |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-172) | Feb 24, 2019 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 30 April, 2014
Treatment: NA
Dosage: POWDER
More Information on Dosage
INCRUSE ELLIPTA family patents
85. Inomax patent expiration
INOMAX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11931377 | MALLINCKRODT HOSP | Methods of administering inhaled nitric oxide gas |
Jun, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846112 | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Jun, 2029
(3 years from now) | |
| US8282966 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Jun, 2029
(3 years from now) | |
| US8293284 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Jun, 2029
(3 years from now) | |
| US8795741 | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Jun, 2029
(3 years from now) | |
| US8431163 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Jun, 2029
(3 years from now) | |
|
US8282966 (Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Dec, 2029
(4 years from now) | |
|
US8293284 (Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Dec, 2029
(4 years from now) | |
|
US8431163 (Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Dec, 2029
(4 years from now) | |
|
US8795741 (Pediatric) | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Dec, 2029
(4 years from now) | |
|
US8846112 (Pediatric) | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Dec, 2029
(4 years from now) | |
|
US11931377 (Pediatric) | MALLINCKRODT HOSP | Methods of administering inhaled nitric oxide gas |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-132) | Dec 21, 2013 |
| Pediatric Exclusivity(PED) | Jun 21, 2014 |
| M(M-167) | Oct 09, 2018 |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Treatment: A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide; A method for treating a pediatric patient who is experiencing idiopathic pulmonary arterial...
Dosage: GAS
How can I launch a generic of INOMAX before it's drug patent expiration?
More Information on Dosage
INOMAX family patents
86. Intermezzo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8242131 | PURDUE PHARMA | Methods of treating middle-of-the-night insomnia |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 23, 2014 |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 23 November, 2011
Treatment: Method of treating middle-of-the-night insomnia
Dosage: TABLET
How can I launch a generic of INTERMEZZO before it's drug patent expiration?
More Information on Dosage
INTERMEZZO family patents
87. Invokamet patent expiration
INVOKAMET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7943582 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 08 August, 2014
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET
How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage
INVOKAMET family patents
88. Invokamet Xr patent expiration
INVOKAMET XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7943582 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| New Indication(I-788) | Oct 29, 2021 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 20 September, 2016
Treatment: Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage
INVOKAMET XR family patents
89. Invokana patent expiration
INVOKANA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7943582 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-733) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Indication(I-809) | Sep 27, 2022 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 29 March, 2013
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET
How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage
INVOKANA family patents
90. Isentress patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7754731 | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7754731 (Pediatric) | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Patient Population(NPP) | Nov 22, 2020 |
| M(M-114) | Mar 28, 2015 |
| New Dosing Schedule(D-167) | May 26, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 20 December, 2013
Treatment: Treatment of hiv infection
Dosage: POWDER; TABLET; TABLET, CHEWABLE
How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage
ISENTRESS family patents
91. Isentress Hd patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7754731 | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7754731 (Pediatric) | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | May 26, 2020 |
| New Patient Population(NPP) | Nov 22, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
NCE-1 date: 22 May, 2020
Market Authorisation Date: 12 October, 2007
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of ISENTRESS HD before it's drug patent expiration?
More Information on Dosage
ISENTRESS HD family patents
92. Isturisa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8314097 | RECORDATI RARE | Organic compounds |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2025 |
| Orphan Drug Exclusivity(ODE-286) | Mar 06, 2027 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: 06 March, 2024
Market Authorisation Date: 06 March, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
ISTURISA family patents
93. Izba patent expiration
IZBA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8722735 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(4 years from now) | |
| US9144561 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Mar, 2029
(3 years from now) | |
| US8754123 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
May, 2029
(3 years from now) | |
| US8178582 | NOVARTIS | Pharmaceutical compositions having desirable bioavailability |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 15, 2017 |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 15 May, 2014
Treatment: NA
Dosage: SOLUTION/DROPS
How can I launch a generic of IZBA before it's drug patent expiration?
More Information on Dosage
IZBA family patents
94. Janumet patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8414921 (Pediatric) | MSD SUB MERCK | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
Jan, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 30 March, 2007
Treatment: NA
Dosage: TABLET
How can I launch a generic of JANUMET before it's drug patent expiration?
More Information on Dosage
JANUMET family patents
95. Jardiance patent expiration
JARDIANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(4 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | Jun 26, 2018 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Indication(I-869) | Aug 18, 2024 |
| M(M-82) | Feb 24, 2025 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-922) | Sep 21, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin
Dosage: TABLET
How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage
JARDIANCE family patents
96. Jatenzo patent expiration
JATENZO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8241664 | TOLMAR | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 27, 2022 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 March, 2019
Treatment: Method of treating testosterone deficiency
Dosage: CAPSULE
More Information on Dosage
JATENZO family patents
97. Jentadueto patent expiration
JENTADUETO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(3 years from now) | |
| US10973827 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(3 years from now) | |
| US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(3 years from now) | |
|
US10022379 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(4 years from now) | |
|
US9415016 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(4 years from now) | |
|
US10973827 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-146) | Jul 30, 2017 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 30 January, 2012
Treatment: Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus
Dosage: TABLET
How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage
JENTADUETO family patents
98. Jentadueto Xr patent expiration
JENTADUETO XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(3 years from now) | |
| US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(3 years from now) | |
|
US10022379 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(4 years from now) | |
|
US9415016 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage
JENTADUETO XR family patents
99. Juluca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Combination(NC) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 21 November, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage
JULUCA family patents
100. Kalydeco patent expiration
KALYDECO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| M(M-14) | May 22, 2028 |
| Pediatric Exclusivity(PED) | Nov 22, 2028 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 23 November, 2027
Market Authorisation Date: 03 May, 2023
Treatment: Treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited i...
Dosage: GRANULE
How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage
KALYDECO family patents
101. Kalydeco patent expiration
KALYDECO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11564916 | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| US10646481 | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| M(M-14) | May 22, 2028 |
| Pediatric Exclusivity(PED) | Nov 22, 2028 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 22 June, 2027
Market Authorisation Date: 20 May, 2019
Treatment: Treatment of cf in a patient age 6 years and older who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in c...
Dosage: TABLET
How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage
KALYDECO family patents
102. Karbinal Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8062667 | AYTU | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(3 years from now) | |
Drugs and Companies using CARBINOXAMINE MALEATE ingredient
Market Authorisation Date: 28 March, 2013
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
KARBINAL ER family patents
103. Kazano patent expiration
Can you believe KAZANO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8900638 | TAKEDA PHARMS USA | Solid preparation comprising alogliptin and metformin hydrochloride |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 25, 2016 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
| M(M-177) | Apr 05, 2019 |
| M(M-300) | Jul 27, 2026 |
Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Treatment: NA
Dosage: TABLET
How can I launch a generic of KAZANO before it's drug patent expiration?
More Information on Dosage
KAZANO family patents
104. Kengreal patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8759316 | CHIESI | Maintenance of platelet inhibition during antiplatelet therapy |
May, 2029
(3 years from now) | |
| US9925265 | CHIESI | Methods of treating or preventing stent thrombosis |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 22, 2020 |
Drugs and Companies using CANGRELOR ingredient
NCE-1 date: 23 June, 2019
Market Authorisation Date: 22 June, 2015
Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a ...
Dosage: POWDER
How can I launch a generic of KENGREAL before it's drug patent expiration?
More Information on Dosage
KENGREAL family patents
105. Kerendia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8436180 | BAYER HLTHCARE | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-279) | Sep 01, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 09, 2026 |
| New Indication(I-970) | Jul 11, 2028 |
| New Strength(NS) | Jul 11, 2028 |
Drugs and Companies using FINERENONE ingredient
NCE-1 date: 09 July, 2025
Market Authorisation Date: 09 July, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
KERENDIA family patents
106. Kimyrsa patent expiration
KIMYRSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
| New Product(NP) | Mar 12, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 12 March, 2021
Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent
Dosage: POWDER
More Information on Dosage
KIMYRSA family patents
107. Kisqali patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(3 years from now) | |
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-783) | Jul 18, 2021 |
| New Indication(I-784) | Jul 18, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-950) | Sep 17, 2027 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 13 March, 2017
Treatment: In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy, for the treatment of adult patients with hr-positive, her2-negative advanced o...
Dosage: TABLET
How can I launch a generic of KISQALI before it's drug patent expiration?
More Information on Dosage
KISQALI family patents
108. Kisqali Femara Co-pack (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(4 years from now) | |
| US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-951) | Sep 17, 2027 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cance...
Dosage: TABLET
How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before it's drug patent expiration?
More Information on Dosage
KISQALI FEMARA CO-PACK (COPACKAGED) family patents
109. Klisyri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851470 | ALMIRALL | Composition and methods for modulating a kinase cascade |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2025 |
| New Dosing Schedule(D-192) | Jun 07, 2027 |
Drugs and Companies using TIRBANIBULIN ingredient
NCE-1 date: 14 December, 2024
Market Authorisation Date: 14 December, 2020
Treatment: Topical treatment of actinic keratosis of the face or scalp
Dosage: OINTMENT
More Information on Dosage
KLISYRI family patents
110. Koselugo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11813246 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(3 years from now) | |
| US12318367 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(3 years from now) | |
| US12220403 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2025 |
| Orphan Drug Exclusivity(ODE-288) | Apr 10, 2027 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
NCE-1 date: 10 April, 2024
Market Authorisation Date: 10 April, 2020
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
KOSELUGO family patents
111. Kyleena patent expiration
KYLEENA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9615965 | BAYER HLTHCARE | Inserter |
Sep, 2029
(4 years from now) | |
| US11850182 | BAYER HLTHCARE | Inserter |
Sep, 2029
(4 years from now) | |
| US10561524 | BAYER HLTHCARE | Inserter |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 16, 2019 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 16 September, 2016
Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to rele...
Dosage: SYSTEM
More Information on Dosage
KYLEENA family patents
112. Kynmobi patent expiration
KYNMOBI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10821074 | SUMITOMO PHARMA AM | Sublingual and buccal film compositions |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: NA
Dosage: FILM
More Information on Dosage
KYNMOBI family patents
113. Kyprolis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9511109 | ONYX PHARMS AMGEN | Combination therapy with peptide epoxyketones |
Oct, 2029
(4 years from now) | |
| USRE47954 | ONYX PHARMS AMGEN | Combination therapy with peptide epoxyketones |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2017 |
| New Indication(I-712) | Jul 24, 2018 |
| New Indication(I-722) | Jan 21, 2019 |
| New Indication(I-723) | Jan 21, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 20, 2019 |
| Orphan Drug Exclusivity(ODE-27) | Jul 20, 2019 |
| New Dosing Schedule(D-172) | Sep 28, 2021 |
| New Indication(I-842) | Aug 20, 2023 |
| M(M-14) | May 22, 2028 |
| Pediatric Exclusivity(PED) | Nov 22, 2028 |
Drugs and Companies using CARFILZOMIB ingredient
NCE-1 date: 23 November, 2027
Market Authorisation Date: 07 June, 2018
Treatment: Kyprolis is indicated in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; Us...
Dosage: POWDER
How can I launch a generic of KYPROLIS before it's drug patent expiration?
More Information on Dosage
KYPROLIS family patents
114. Lamictal Odt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7919115 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jan, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | May 18, 2018 |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 08 May, 2009
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING
How can I launch a generic of LAMICTAL ODT before it's drug patent expiration?
More Information on Dosage
LAMICTAL ODT family patents
115. Lamictal Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8637512 | GLAXOSMITHKLINE LLC | Formulations and method of treatment |
Jan, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 29, 2012 |
| Pediatric Exclusivity(PED) | Nov 29, 2012 |
| New Indication(I-622) | Jan 29, 2013 |
| New Indication(I-644) | Apr 25, 2014 |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 29 May, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of LAMICTAL XR before it's drug patent expiration?
More Information on Dosage
LAMICTAL XR family patents
116. Leqvio patent expiration
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8106022 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 22 December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (hefh), by inhibiting expression of the pcsk9 gen...
Dosage: SOLUTION
More Information on Dosage
LEQVIO family patents
117. Lo Loestrin Fe patent expiration
LO LOESTRIN FE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 21, 2013 |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 21 October, 2010
Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET
How can I launch a generic of LO LOESTRIN FE before it's drug patent expiration?
More Information on Dosage
LO LOESTRIN FE family patents
118. Lo Minastrin Fe patent expiration
LO MINASTRIN FE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(3 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 24 July, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET, CHEWABLE, TABLET
More Information on Dosage
LO MINASTRIN FE family patents
119. Lonhala Magnair Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940110 | SUMITOMO PHARMA AM | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION
More Information on Dosage
LONHALA MAGNAIR KIT family patents
120. Lonsurf patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE46284 | TAIHO ONCOLOGY | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2020 |
| New Indication(I-794) | Feb 22, 2022 |
| Orphan Drug Exclusivity(ODE-229) | Feb 22, 2026 |
Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient
NCE-1 date: 23 September, 2019
Market Authorisation Date: 22 September, 2015
Treatment: Treatment of metastatic colorectal cancer alone or with bevacizumab in patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological thera...
Dosage: TABLET
How can I launch a generic of LONSURF before it's drug patent expiration?
More Information on Dosage
LONSURF family patents
121. Lumify patent expiration
LUMIFY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11596600 | BAUSCH AND LOMB INC | Vasoconstriction compositions and methods of use |
Jul, 2029
(3 years from now) | |
| US11833245 | BAUSCH AND LOMB INC | Vasoconstriction compositions and methods of use |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 22, 2020 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 December, 2017
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS
How can I launch a generic of LUMIFY before it's drug patent expiration?
More Information on Dosage
LUMIFY family patents
122. Lumify Preservative Free patent expiration
LUMIFY PRESERVATIVE FREE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11596600 | BAUSCH AND LOMB INC | Vasoconstriction compositions and methods of use |
Jul, 2029
(3 years from now) | |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 19 April, 2024
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS
More Information on Dosage
LUMIFY PRESERVATIVE FREE family patents
123. Lymphoseek Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9439985 | CARDINAL HEALTH 414 | Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran |
Jan, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-687) | Jun 13, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2018 |
| Orphan Drug Exclusivity(ODE) | Jun 13, 2021 |
| Orphan Drug Exclusivity(ODE-67) | Jun 13, 2021 |
| New Patient Population(NPP) | May 19, 2024 |
Drugs and Companies using TECHNETIUM TC-99M TILMANOCEPT ingredient
NCE-1 date: 13 March, 2017
Market Authorisation Date: 13 March, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LYMPHOSEEK KIT family patents
124. Lynparza patent expiration
LYNPARZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11975001 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(4 years from now) | |
| US11633396 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one |
Oct, 2029
(4 years from now) | |
| US8475842 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Dec, 2029
(4 years from now) | |
| US12048695 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(4 years from now) | |
| US12178816 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(4 years from now) | |
| US12144810 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Product(NP) | Aug 17, 2020 |
| New Indication(I-762) | Jan 12, 2021 |
| New Indication(I-776) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE-83) | Dec 19, 2021 |
| New Indication(I-818) | Dec 27, 2022 |
| New Indication(I-831) | May 08, 2023 |
| New Indication(I-832) | May 19, 2023 |
| Orphan Drug Exclusivity(ODE-180) | Aug 17, 2024 |
| Orphan Drug Exclusivity(ODE-181) | Aug 17, 2024 |
| New Indication(I-885) | Mar 11, 2025 |
| Orphan Drug Exclusivity(ODE-226) | Dec 19, 2025 |
| New Indication(I-914) | May 31, 2026 |
| Orphan Drug Exclusivity(ODE-283) | Dec 27, 2026 |
| Orphan Drug Exclusivity(ODE-306) | May 08, 2027 |
Drugs and Companies using OLAPARIB ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 17 August, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage
LYNPARZA family patents
125. Milprosa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10548904 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Feb, 2029
(3 years from now) | |
| US10537584 | FERRING PHARMS INC | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2023 |
Drugs and Companies using PROGESTERONE ingredient
Market Authorisation Date: 29 April, 2020
Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women
Dosage: SYSTEM
More Information on Dosage
MILPROSA family patents
126. Miplyffa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11045460 | ZEVRA DENMARK | Use of Hsp70 as a regulator of enzymatic activity |
Aug, 2029
(3 years from now) | |
| US9884058 | ZEVRA DENMARK | Use of Hsp70 as a regulator of enzymatic activity |
Jun, 2029
(3 years from now) | |
| US9289472 | ZEVRA DENMARK | Use of HSP70 as a regulator of enzymatic activity |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 20, 2029 |
| Orphan Drug Exclusivity(ODE-496) | Sep 20, 2031 |
Drugs and Companies using ARIMOCLOMOL CITRATE ingredient
NCE-1 date: 20 September, 2028
Market Authorisation Date: 20 September, 2024
Treatment: Use of arimoclomol, in combination with miglustat, for treatment of neurological manifestations of niemann-pick disease type c (npc)
Dosage: CAPSULE
More Information on Dosage
MIPLYFFA family patents
127. Mirapex Er patent expiration
MIRAPEX ER's oppositions filed in EPO
MIRAPEX ER IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679533 | BOEHRINGER INGELHEIM | Pramipexole once-daily dosage form |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 19, 2013 |
| New Indication(I-623) | Mar 19, 2013 |
Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 February, 2010
Treatment: Treatment of parkinson's disease
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of MIRAPEX ER before it's drug patent expiration?
More Information on Dosage
MIRAPEX ER family patents
128. Mirena patent expiration
MIRENA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9615965 | BAYER HLTHCARE | Inserter |
Sep, 2029
(4 years from now) | |
| US11850182 | BAYER HLTHCARE | Inserter |
Sep, 2029
(4 years from now) | |
| US10561524 | BAYER HLTHCARE | Inserter |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-610) | Oct 01, 2012 |
| New Dosing Schedule(D-181) | Aug 20, 2023 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 06 December, 2000
Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to rele...
Dosage: SYSTEM
More Information on Dosage
MIRENA family patents
129. Mitosol patent expiration
Can you believe MITOSOL received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649428 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
May, 2029
(3 years from now) | |
| US7806265 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Feb 07, 2019 |
| Orphan Drug Exclusivity(ODE-21) | Feb 07, 2019 |
Drugs and Companies using MITOMYCIN ingredient
Market Authorisation Date: 07 February, 2012
Treatment: Mitosol is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. it is intended for topical application to the site of glaucoma filtration surgery
Dosage: FOR SOLUTION
More Information on Dosage
MITOSOL family patents
130. Monoferric patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8815301 | PHARMACOSMOS | Stable iron oligosaccharide compound |
Aug, 2029
(3 years from now) | |
| US10414831 | PHARMACOSMOS | Stable iron oligosaccharide compound |
Mar, 2029
(3 years from now) | |
| US12030962 | PHARMACOSMOS | Stable iron oligosaccharide compound |
Mar, 2029
(3 years from now) | |
| US11851504 | PHARMACOSMOS | Stable iron oligosaccharide compound |
Mar, 2029
(3 years from now) | |
Drugs and Companies using FERRIC DERISOMALTOSE ingredient
Market Authorisation Date: 16 January, 2020
Treatment: Method of treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, who have non-hemodialysis dependent chronic kidney d...
Dosage: SOLUTION
More Information on Dosage
MONOFERRIC family patents
131. Moxeza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9114168 | HARROW EYE | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
May, 2029
(3 years from now) | |
| US8450311 | HARROW EYE | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 19, 2013 |
| Pediatric Exclusivity(PED) | May 19, 2014 |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 19 November, 2010
Treatment: NA
Dosage: SOLUTION/DROPS
How can I launch a generic of MOXEZA before it's drug patent expiration?
More Information on Dosage
MOXEZA family patents
132. Multaq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8410167 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Apr, 2029
(3 years from now) | |
| US9107900 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2014 |
Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient
NCE-1 date: 01 July, 2013
Market Authorisation Date: 01 July, 2009
Treatment: Treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Reducti...
Dosage: TABLET
How can I launch a generic of MULTAQ before it's drug patent expiration?
More Information on Dosage
MULTAQ family patents
133. Mycapssa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265812 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(4 years from now) | |
| US8535695 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(4 years from now) | |
| US11986529 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(4 years from now) | |
| US11969471 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(4 years from now) | |
| US8329198 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(4 years from now) | |
| US9566246 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 26, 2023 |
| Orphan Drug Exclusivity(ODE-474) | Jun 26, 2027 |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 26 June, 2020
Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
MYCAPSSA family patents
134. Mydayis patent expiration
MYDAYIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846100 | TAKEDA PHARMS USA | Controlled dose drug delivery system |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 20, 2020 |
| M(M-248) | Sep 13, 2022 |
| Pediatric Exclusivity(PED) | Mar 13, 2023 |
Market Authorisation Date: 20 June, 2017
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of MYDAYIS before it's drug patent expiration?
More Information on Dosage
MYDAYIS family patents
135. Myrbetriq patent expiration
MYRBETRIQ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11707451 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
| US12097189 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
| US10842780 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
| US12059409 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(4 years from now) | |
|
US8772315 (Pediatric) | APGDI | Pharmaceutical composition for treating overactive bladder |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
| New Indication(I-777) | Apr 27, 2021 |
| New Indication(I-855) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
NCE-1 date: 26 September, 2023
Market Authorisation Date: 28 June, 2012
Treatment: Administration of an extended release tablet for the treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older and weighing 35 kg or more; Administration of an e...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage
MYRBETRIQ family patents
136. Namenda Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8039009 | ABBVIE | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(3 years from now) | |
|
US8039009 (Pediatric) | ABBVIE | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 21, 2013 |
| M(M-138) | Jul 03, 2017 |
| Pediatric Exclusivity(PED) | Jan 03, 2018 |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 June, 2010
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of NAMENDA XR before it's drug patent expiration?
More Information on Dosage
NAMENDA XR family patents
137. Namzaric patent expiration
NAMZARIC's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8039009 | ABBVIE | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(3 years from now) | |
| US8058291 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Dec, 2029
(4 years from now) | |
|
US8039009 (Pediatric) | ABBVIE | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(4 years from now) | |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 July, 2016
Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of NAMZARIC before it's drug patent expiration?
More Information on Dosage
NAMZARIC family patents
138. Nerlynx patent expiration
NERLYNX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265784 | PUMA BIOTECH | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 17, 2022 |
| New Indication(I-823) | Feb 25, 2023 |
| New Dosing Schedule(D-182) | Jun 28, 2024 |
Drugs and Companies using NERATINIB MALEATE ingredient
NCE-1 date: 17 July, 2021
Market Authorisation Date: 17 July, 2017
Treatment: Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the me...
Dosage: TABLET
How can I launch a generic of NERLYNX before it's drug patent expiration?
More Information on Dosage
NERLYNX family patents
139. Nesina patent expiration
Can you believe NESINA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8697125 | TAKEDA PHARMS USA | Tablet preparation without causing a tableting trouble |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
| M(M-177) | Apr 05, 2019 |
| M(M-300) | Jul 27, 2026 |
Drugs and Companies using ALOGLIPTIN BENZOATE ingredient
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Treatment: NA
Dosage: TABLET
How can I launch a generic of NESINA before it's drug patent expiration?
More Information on Dosage
NESINA family patents
140. Neuraceq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7907135 | LIFE MOLECULAR | Image display and image displaying method for gradation correction |
Mar, 2029
(3 years from now) | |
| US7807135 | LIFE MOLECULAR | Stilbene derivatives and their use for binding and imaging amyloid plaques |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2019 |
Drugs and Companies using FLORBETABEN F-18 ingredient
NCE-1 date: 21 March, 2018
Market Authorisation Date: 19 March, 2014
Treatment: Neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment
Dosage: SOLUTION
More Information on Dosage
NEURACEQ family patents
141. Nexterone patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7635773 | BAXTER HLTHCARE | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
Drugs and Companies using AMIODARONE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 December, 2008
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NEXTERONE family patents
142. Nicorette patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8940772 | HALEON US HOLDINGS | Nicotine lozenge composition |
Apr, 2029
(3 years from now) | |
| US8501164 | HALEON US HOLDINGS | Nicotine lozenge compositions |
Jun, 2029
(3 years from now) | |
Drugs and Companies using NICOTINE POLACRILEX ingredient
Market Authorisation Date: 18 May, 2009
Treatment: NA
Dosage: TROCHE/LOZENGE
How can I launch a generic of NICORETTE before it's drug patent expiration?
More Information on Dosage
NICORETTE family patents
143. Ninlaro patent expiration
NINLARO's oppositions filed in EPO
Can you believe NINLARO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7442830 | TAKEDA PHARMS USA | Proteasome inhibitors |
Nov, 2029
(4 years from now) | |
| US8859504 | TAKEDA PHARMS USA | Boronate ester compounds and pharmaceutical compositions thereof |
Jun, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9175017 | TAKEDA PHARMS USA | Boronate ester compounds and pharmaceutical compositions thereof |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 20, 2022 |
| Orphan Drug Exclusivity(ODE-103) | Nov 20, 2022 |
Drugs and Companies using IXAZOMIB CITRATE ingredient
NCE-1 date: 21 November, 2019
Market Authorisation Date: 20 November, 2015
Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
Dosage: CAPSULE
How can I launch a generic of NINLARO before it's drug patent expiration?
More Information on Dosage
NINLARO family patents
144. Nitrolingual Pumpspray patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7872049 | POHL BOSKAMP | Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate |
Mar, 2029
(3 years from now) | |
Drugs and Companies using NITROGLYCERIN ingredient
Market Authorisation Date: 10 January, 1997
Treatment: Method of treating angina pectoris
Dosage: SPRAY, METERED
How can I launch a generic of NITROLINGUAL PUMPSPRAY before it's drug patent expiration?
More Information on Dosage
NITROLINGUAL PUMPSPRAY family patents
145. Nocdurna patent expiration
NOCDURNA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11963995 | FERRING PHARMS INC | Methods comprising desmopressin |
May, 2029
(3 years from now) | |
| US10137167 | FERRING PHARMS INC | Methods comprising desmopressin |
May, 2029
(3 years from now) | |
| US11020448 | FERRING PHARMS INC | Methods comprising desmopressin |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 21, 2021 |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 21 June, 2018
Treatment: Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration
Dosage: TABLET
More Information on Dosage
NOCDURNA family patents
146. Noxafil patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750822 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US10117951 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents
147. Nucynta Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8536130 (Pediatric) | COLLEGIUM PHARM INC | Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Dosage Form(NDF) | Aug 25, 2014 |
| New Indication(I-656) | Aug 28, 2015 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 20 November, 2012
Market Authorisation Date: 25 August, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of NUCYNTA ER before it's drug patent expiration?
More Information on Dosage
NUCYNTA ER family patents
148. Nuzyra patent expiration
Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9724358 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US10124014 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US9265740 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 03 October, 2027
Market Authorisation Date: 02 October, 2018
Treatment: Treatment of bacterial skin and skin structure infections; Treatment of bacterial skin and skin structure infection
Dosage: TABLET; POWDER
More Information on Dosage
NUZYRA family patents
149. Odomzo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8178563 | SUN PHARM | Compounds and compositions as hedgehog pathway modulators |
Jul, 2029
(3 years from now) | |
| US8063043 | SUN PHARM | Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2020 |
Drugs and Companies using SONIDEGIB PHOSPHATE ingredient
NCE-1 date: 25 July, 2019
Market Authorisation Date: 24 July, 2015
Treatment: Treatment of basal cell carcinoma
Dosage: CAPSULE
More Information on Dosage
ODOMZO family patents
150. Ofev patent expiration
OFEV's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10105323 | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Jun, 2029
(3 years from now) | |
| US9907756 | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Jun, 2029
(3 years from now) | |
|
US9907756 (Pediatric) | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Dec, 2029
(4 years from now) | |
|
US10105323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
| New Indication(I-805) | Sep 06, 2022 |
| New Indication(I-825) | Mar 09, 2023 |
| Orphan Drug Exclusivity(ODE-261) | Sep 06, 2026 |
| Pediatric Exclusivity(PED) | Mar 06, 2027 |
Drugs and Companies using NINTEDANIB ESYLATE ingredient
NCE-1 date: 06 March, 2026
Market Authorisation Date: 15 October, 2014
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of OFEV before it's drug patent expiration?
More Information on Dosage
OFEV family patents
151. Ofirmev patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9610265 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
May, 2029
(3 years from now) | |
|
US9987238 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 02, 2013 |
| M(M-196) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 02 November, 2010
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of OFIRMEV before it's drug patent expiration?
More Information on Dosage
OFIRMEV family patents
152. Oleptro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8133893 | ANGELINI PHARMA | Trazodone and trazodone hydrochloride in purified form |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 02, 2013 |
Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 02 February, 2010
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of OLEPTRO before it's drug patent expiration?
More Information on Dosage
OLEPTRO family patents
153. Olumiant patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420629 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 31, 2023 |
| New Indication(I-891) | May 10, 2025 |
| New Indication(I-890) | Jun 13, 2025 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: 31 May, 2022
Market Authorisation Date: 08 October, 2019
Treatment: Treatment of rheumatoid arthritis
Dosage: TABLET
How can I launch a generic of OLUMIANT before it's drug patent expiration?
More Information on Dosage
OLUMIANT family patents
154. Olysio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148399 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-697) | Nov 05, 2017 |
| New Dosing Schedule(D-151) | Oct 05, 2018 |
| New Indication(I-717) | Oct 05, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2018 |
| M(M-171) | Feb 26, 2019 |
| M(M-179) | May 20, 2019 |
Drugs and Companies using SIMEPREVIR SODIUM ingredient
NCE-1 date: 22 November, 2017
Market Authorisation Date: 22 November, 2013
Treatment: Method of treating hepatitis c
Dosage: CAPSULE
More Information on Dosage
OLYSIO family patents
155. Omlonti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8648097 | OCUVEX THERAP | Pyridylaminoacetic acid compound |
Oct, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685986 | OCUVEX THERAP | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: 22 September, 2026
Market Authorisation Date: 22 September, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
OMLONTI family patents
156. Onexton patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9504704 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(3 years from now) | |
| US10220049 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(3 years from now) | |
| US8288434 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Aug, 2029
(3 years from now) | |
| US9561208 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(3 years from now) | |
| US10137142 | BAUSCH | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Jun, 2029
(3 years from now) | |
Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 23 October, 2008
Treatment: Treatment of acne; Topical treatment of acne vulgaris in patients 12 years or older
Dosage: GEL
How can I launch a generic of ONEXTON before it's drug patent expiration?
More Information on Dosage
ONEXTON family patents
157. Ongentys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8168793 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
Apr, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8524746 | AMNEAL | Dosage regimen for COMT inhibitors |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson’s disease experiencing off episodes
Dosage: CAPSULE
More Information on Dosage
ONGENTYS family patents
158. Onpattro patent expiration
ONPATTRO's oppositions filed in EPO
ONPATTRO IPR and PTAB Proceedings
Can you believe ONPATTRO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10240152 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8822668 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US8741866 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(4 years from now) | |
| US9364435 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US9234196 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(4 years from now) | |
| US11141378 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US8492359 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US8058069 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity(ODE-197) | Aug 10, 2025 |
| M(M-270) | Jan 13, 2026 |
Drugs and Companies using PATISIRAN SODIUM ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION
More Information on Dosage
ONPATTRO family patents
159. Onureg patent expiration
ONUREG's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12053482 | BRISTOL | Oral formulations of cytidine analogs and methods of use thereof |
May, 2029
(3 years from now) | |
| US11571436 | BRISTOL | Oral formulations of cytidine analogs and methods of use thereof |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 01, 2023 |
| Orphan Drug Exclusivity(ODE-320) | Sep 01, 2027 |
Drugs and Companies using AZACITIDINE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not a...
Dosage: TABLET
How can I launch a generic of ONUREG before it's drug patent expiration?
More Information on Dosage
ONUREG family patents
160. Onyda Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8062667 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(3 years from now) | |
Drugs and Companies using CLONIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 May, 2024
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ONYDA XR family patents
161. Onzetra Xsail patent expiration
ONZETRA XSAIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10076615 | CURRAX | Nasal delivery |
Jul, 2029
(3 years from now) | |
| US8550073 | CURRAX | Nasal delivery |
Oct, 2029
(4 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Method of delivering sumatriptan to a nasal cavity
Dosage: POWDER
More Information on Dosage
ONZETRA XSAIL family patents
162. Opana Er patent expiration
OPANA ER's oppositions filed in EPO
OPANA ER IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851482 | ENDO PHARMS | Method for making analgesics |
Jul, 2029
(3 years from now) | |
| US8871779 | ENDO PHARMS | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
Nov, 2029
(4 years from now) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 December, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OPANA ER family patents
163. Opana Er patent expiration
OPANA ER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8871779 | ENDO OPERATIONS | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
Nov, 2029
(4 years from now) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 June, 2006
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OPANA ER family patents
164. Opsumit patent expiration
OPSUMIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268847 | ACTELION | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 18, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 18, 2020 |
| Orphan Drug Exclusivity(ODE-54) | Oct 18, 2020 |
| M(M-187) | Feb 28, 2028 |
Drugs and Companies using MACITENTAN ingredient
NCE-1 date: 18 October, 2017
Market Authorisation Date: 18 October, 2013
Treatment: Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties
Dosage: TABLET
How can I launch a generic of OPSUMIT before it's drug patent expiration?
More Information on Dosage
OPSUMIT family patents
165. Opsynvi patent expiration
OPSYNVI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268847 | ACTELION | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2027 |
| Orphan Drug Exclusivity(ODE-475) | Mar 22, 2031 |
Drugs and Companies using MACITENTAN; TADALAFIL ingredient
Market Authorisation Date: 22 March, 2024
Treatment: Method of treating pulmonary arterial hypertension comprising administering a combination of macitentan and tadalafil
Dosage: TABLET
More Information on Dosage
OPSYNVI family patents
166. Orbactiv patent expiration
ORBACTIV's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 06 August, 2014
Treatment: Treatment of bacterial skin and skin structure infections using a single dose
Dosage: POWDER
More Information on Dosage
ORBACTIV family patents
167. Oriahnn (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7419983 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
NCE-1 date: 23 July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of ORIAHNN (COPACKAGED) before it's drug patent expiration?
More Information on Dosage
ORIAHNN (COPACKAGED) family patents
168. Orilissa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7419983 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 23 July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis
Dosage: TABLET
How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage
ORILISSA family patents
169. Orkambi patent expiration
ORKAMBI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192606 | VERTEX PHARMS INC | Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Sep, 2029
(4 years from now) | |
| US8846718 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Jul, 2029
(3 years from now) | |
| US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
|
US8653103 (Pediatric) | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Jun, 2029
(3 years from now) | |
|
US9150552 (Pediatric) | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Jun, 2029
(3 years from now) | |
|
US10597384 (Pediatric) | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Jun, 2029
(3 years from now) | |
|
US12065432 (Pediatric) | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Jun, 2029
(3 years from now) | |
|
US10076513 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
Jun, 2029
(3 years from now) | |
|
US11052075 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 02, 2025 |
| Pediatric Exclusivity(PED) | Jun 13, 2028 |
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2020 |
| M(M-218) | Jan 25, 2021 |
| New Product(NP) | Aug 07, 2021 |
| Orphan Drug Exclusivity(ODE-93) | Jul 02, 2022 |
| Orphan Drug Exclusivity(ODE) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-123) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-195) | Aug 07, 2025 |
| New Strength(NS) | Sep 02, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Jan 02, 2028 |
| M(M-14) | Dec 13, 2027 |
| Orphan Drug Exclusivity(ODE-408) | Sep 02, 2029 |
Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient
NCE-1 date: 02 January, 2022
Market Authorisation Date: 28 September, 2016
Treatment: Treatment of cystic fibrosis in a patient age 1-5 years who is homozygous for the f508del mutation in the cftr gene using the dosage unit comprising lumacaftor and ivacaftor as recited in claim 1 of u...
Dosage: TABLET; GRANULE
More Information on Dosage
ORKAMBI family patents
170. Orlynvah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7795243 | ITERUM THERAP | Penem prodrugs |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2029 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 25, 2034 |
Drugs and Companies using PROBENECID; SULOPENEM ETZADROXIL ingredient
NCE-1 date: 25 October, 2033
Market Authorisation Date: 25 October, 2024
Treatment: Use in treating uncomplicated urinary tract infections caused by escherichia coli, klebsiella pneumoniae, or proteus mirabilis
Dosage: TABLET
More Information on Dosage
ORLYNVAH family patents
171. Oseni patent expiration
Can you believe OSENI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8637079 | TAKEDA PHARMS USA | Solid preparation comprising alogliptin and pioglitazone |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 25, 2016 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
| M(M-177) | Apr 05, 2019 |
Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Treatment: NA
Dosage: TABLET
More Information on Dosage
OSENI family patents
172. Otiprio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9603796 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11369566 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2029
(3 years from now) | |
| US9233068 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders |
Dec, 2029
(4 years from now) | |
| US9205048 | ALK ABELLO | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 10, 2018 |
| New Indication(I-770) | Mar 02, 2021 |
Drugs and Companies using CIPROFLOXACIN ingredient
Market Authorisation Date: 10 December, 2015
Treatment: Treatment of pediatric patients with otitis media with effusion undergoing tympanostomy tube placement; The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas a...
Dosage: INJECTABLE, SUSPENSION
More Information on Dosage
OTIPRIO family patents
173. Otrexup patent expiration
OTREXUP's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10709844 | OTTER PHARMS | Injector safety device |
Mar, 2029
(3 years from now) | |
| US11684723 | OTTER PHARMS | Injector safety device |
Mar, 2029
(3 years from now) | |
| US9867949 | OTTER PHARMS | Injector safety device |
Mar, 2029
(3 years from now) | |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 07 November, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
OTREXUP family patents
174. Oxlumo patent expiration
Can you believe OXLUMO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-901) | Oct 06, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2025 |
| Orphan Drug Exclusivity(ODE-339) | Nov 23, 2027 |
| Orphan Drug Exclusivity(ODE-415) | Oct 06, 2029 |
Drugs and Companies using LUMASIRAN SODIUM ingredient
NCE-1 date: 23 November, 2024
Market Authorisation Date: 23 November, 2020
Treatment: Treatment of primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION
More Information on Dosage
OXLUMO family patents
175. Pennsaid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8741956 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(3 years from now) | |
| US9370501 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(3 years from now) | |
| US8217078 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(3 years from now) | |
| US9375412 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(3 years from now) | |
| US8618164 | HORIZON | Treatment of pain with topical diclofenac compounds |
Jul, 2029
(3 years from now) | |
| US9415029 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Nov 04, 2012 |
| New Product(NP) | Jan 16, 2017 |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 16 January, 2014
Treatment: Combination use of topical diclofenac on the knee and administration of an oral nsaid.; Use of topical diclofenac sodium for treating pain; Use of topical diclofenac on the knee and a second topical p...
Dosage: SOLUTION
How can I launch a generic of PENNSAID before it's drug patent expiration?
More Information on Dosage
PENNSAID family patents
176. Pennsaid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618164 | NUVO PHARMS INC | Treatment of pain with topical diclofenac compounds |
Jul, 2029
(3 years from now) | |
| US8217078 | NUVO PHARMS INC | Treatment of pain with topical diclofenac |
Jul, 2029
(3 years from now) | |
| US8741956 | NUVO PHARMS INC | Treatment of pain with topical diclofenac |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Nov 04, 2012 |
| New Product(NP) | Jan 16, 2017 |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 04 November, 2009
Treatment: Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Use of topical diclofenac on the knee and a second topical medication on the same knee; Combination...
Dosage: SOLUTION
How can I launch a generic of PENNSAID before it's drug patent expiration?
More Information on Dosage
PENNSAID family patents
177. Piqray patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| New Indication(I-937) | Jan 18, 2027 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 25 May, 2023
Market Authorisation Date: 24 May, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
PIQRAY family patents
178. Ponvory patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43728 | VANDA PHARMS INC | Thiazolidin-4-one derivatives |
Nov, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
PONVORY family patents
179. Prestalia patent expiration
PRESTALIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7846961 | ADHERA | α crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 21, 2018 |
Drugs and Companies using AMLODIPINE BESYLATE; PERINDOPRIL ARGININE ingredient
Market Authorisation Date: 21 January, 2015
Treatment: Treatment of hypertension
Dosage: TABLET
How can I launch a generic of PRESTALIA before it's drug patent expiration?
More Information on Dosage
PRESTALIA family patents
180. Prevymis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46791 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
Jan, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2022 |
| Orphan Drug Exclusivity(ODE-165) | Nov 08, 2024 |
| New Indication(I-916) | Jun 05, 2026 |
| New Dosing Schedule(D-189) | Aug 02, 2026 |
| New Product(NP) | Aug 30, 2027 |
| New Patient Population(NPP) | Aug 30, 2027 |
| ODE*(ODE*) | Jun 05, 2030 |
| Orphan Drug Exclusivity(ODE-423) | Jun 05, 2030 |
| Orphan Drug Exclusivity(ODE-495) | Aug 30, 2031 |
| Orphan Drug Exclusivity(ODE-497) | Aug 30, 2031 |
Drugs and Companies using LETERMOVIR ingredient
NCE-1 date: 08 November, 2021
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: SOLUTION; TABLET
More Information on Dosage
PREVYMIS family patents
181. Prevymis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46791 | MSD | Substituted dihydroquinazolines |
Jan, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2022 |
| Orphan Drug Exclusivity(ODE-165) | Nov 08, 2024 |
| New Indication(I-916) | Jun 05, 2026 |
| New Dosing Schedule(D-189) | Aug 02, 2026 |
| New Product(NP) | Aug 30, 2027 |
| New Patient Population(NPP) | Aug 30, 2027 |
| ODE*(ODE*) | Jun 05, 2030 |
| Orphan Drug Exclusivity(ODE-423) | Jun 05, 2030 |
| Orphan Drug Exclusivity(ODE-495) | Aug 30, 2031 |
| Orphan Drug Exclusivity(ODE-497) | Aug 30, 2031 |
Drugs and Companies using LETERMOVIR ingredient
Market Authorisation Date: 30 August, 2024
Treatment: NA
Dosage: PELLETS
More Information on Dosage
PREVYMIS family patents
182. Prezcobix patent expiration
PREZCOBIX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148374 | JANSSEN PRODS | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
Drugs and Companies using COBICISTAT; DARUNAVIR ETHANOLATE ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 21 March, 2025
Treatment: Treatment of hiv infection in adults and pediatric patients weighing at least 40kg using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET
How can I launch a generic of PREZCOBIX before it's drug patent expiration?
More Information on Dosage
PREZCOBIX family patents
183. Pylarify patent expiration
Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9861713 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Jul, 2029
(3 years from now) | |
| US12070513 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 26 May, 2025
Market Authorisation Date: 26 May, 2021
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
Dosage: SOLUTION
More Information on Dosage
PYLARIFY family patents
184. Qbrexza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618160 | JOURNEY | Topical glycopyrrolate formulations |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2021 |
Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient
Market Authorisation Date: 28 June, 2018
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: CLOTH
How can I launch a generic of QBREXZA before it's drug patent expiration?
More Information on Dosage
QBREXZA family patents
185. Qelbree patent expiration
QELBREE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458143 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(3 years from now) | |
| US12121523 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(3 years from now) | |
| US11324753 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2026 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2025
Market Authorisation Date: 02 April, 2021
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
QELBREE family patents
186. Qsymia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8580299 | VIVUS LLC | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2029
(3 years from now) | |
| US8580298 | VIVUS LLC | Low dose topiramate/phentermine composition and methods of use thereof |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 17, 2015 |
| New Patient Population(NPP) | Jun 24, 2025 |
| M(M-308) | Sep 13, 2027 |
Drugs and Companies using PHENTERMINE HYDROCHLORIDE; TOPIRAMATE ingredient
Market Authorisation Date: 17 July, 2012
Treatment: For chronic weight management in adults with bmi >=30 kg/m2, and patients age 12-17 with bmi >=30 kg/m2 and in the 95th percentile or greater (standardized for age and sex), each having a weight-relat...
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of QSYMIA before it's drug patent expiration?
More Information on Dosage
QSYMIA family patents
187. Qtern patent expiration
QTERN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-175) | Apr 05, 2019 |
| New Combination(NC) | Feb 27, 2020 |
| New Indication(I-804) | May 02, 2022 |
| New Strength(NS) | May 02, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 02 May, 2019
Treatment: NA
Dosage: TABLET
How can I launch a generic of QTERN before it's drug patent expiration?
More Information on Dosage
QTERN family patents
188. Qternmet Xr patent expiration
QTERNMET XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 02, 2022 |
Market Authorisation Date: 02 May, 2019
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
QTERNMET XR family patents
189. Quartette patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8415332 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 28, 2016 |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 28 March, 2013
Treatment: NA
Dosage: TABLET
How can I launch a generic of QUARTETTE before it's drug patent expiration?
More Information on Dosage
QUARTETTE family patents
190. Quillivant Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8062667 | NEXTWAVE | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Sep 27, 2015 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 September, 2012
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE
How can I launch a generic of QUILLIVANT XR before it's drug patent expiration?
More Information on Dosage
QUILLIVANT XR family patents
191. Raldesy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8133893 | KAMAT | Trazodone and trazodone hydrochloride in purified form |
Mar, 2029
(3 years from now) | |
Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 November, 2024
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
RALDESY family patents
192. Rasuvo patent expiration
RASUVO's oppositions filed in EPO
RASUVO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8664231 | MEDEXUS | Concentrated methotrexate solutions |
Jun, 2029
(3 years from now) | |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 10 July, 2014
Treatment: Subcutaneous injection of methotrexate
Dosage: SOLUTION
More Information on Dosage
RASUVO family patents
193. Relistor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420663 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(4 years from now) | |
| US8822490 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(4 years from now) | |
| US9492445 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(4 years from now) | |
| US9180125 | SALIX PHARMS | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
| New Product(NP) | Jul 19, 2019 |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
NCE-1 date: 24 April, 2012
Market Authorisation Date: 27 September, 2010
Treatment: Treatment of opioid-induced constipation
Dosage: SOLUTION
How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage
RELISTOR family patents
194. Relistor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9180125 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(4 years from now) | |
| US9492445 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(4 years from now) | |
| US9724343 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(4 years from now) | |
| US8420663 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
| New Product(NP) | Jul 19, 2019 |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
Market Authorisation Date: 19 July, 2016
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET
How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage
RELISTOR family patents
195. Remodulin patent expiration
REMODULIN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7999007 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Mar, 2029
(3 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 28 September, 2023
Treatment: Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration
Dosage: INJECTABLE
How can I launch a generic of REMODULIN before it's drug patent expiration?
More Information on Dosage
REMODULIN family patents
196. Rexulti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE48059 (Pediatric) | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-186) | Sep 23, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 10, 2020 |
| New Patient Population(NPP) | Dec 27, 2024 |
| New Indication(I-913) | May 10, 2026 |
| Pediatric Exclusivity(PED) | Nov 10, 2026 |
| M(M-14) | May 08, 2027 |
| M(M-315) | May 09, 2028 |
Drugs and Companies using BREXPIPRAZOLE ingredient
NCE-1 date: 10 November, 2025
Market Authorisation Date: 10 July, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of REXULTI before it's drug patent expiration?
More Information on Dosage
REXULTI family patents
197. Rezurock patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8357693 | KADMON PHARMS LLC | Pharmacokinetically improved compounds |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2026 |
| Orphan Drug Exclusivity(ODE-362) | Jul 16, 2028 |
Drugs and Companies using BELUMOSUDIL MESYLATE ingredient
NCE-1 date: 16 July, 2025
Market Authorisation Date: 16 July, 2021
Treatment: For the treatment of chronic graft versus hold disease
Dosage: TABLET
More Information on Dosage
REZUROCK family patents
198. Rukobia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168615 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2025 |
Drugs and Companies using FOSTEMSAVIR TROMETHAMINE ingredient
NCE-1 date: 02 July, 2024
Market Authorisation Date: 02 July, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
RUKOBIA family patents
199. Ryzodeg 70/30 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7615532 | NOVO | Insulin derivatives |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 25 September, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
RYZODEG 70/30 family patents
200. Savella patent expiration
Can you believe SAVELLA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7994220 | ABBVIE | Milnacipran for the long-term treatment of fibromyalgia syndrome |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 14, 2014 |
Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient
NCE-1 date: 14 January, 2013
Market Authorisation Date: 14 January, 2009
Treatment: Management of fibromyalgia
Dosage: TABLET
How can I launch a generic of SAVELLA before it's drug patent expiration?
More Information on Dosage
SAVELLA family patents
201. Scenesse patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8334265 | CLIVUNEL INC | Method of treatment of photodermatoses |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2024 |
| Orphan Drug Exclusivity(ODE-270) | Oct 08, 2026 |
Drugs and Companies using AFAMELANOTIDE ingredient
NCE-1 date: 09 October, 2023
Market Authorisation Date: 08 October, 2019
Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)
Dosage: IMPLANT
More Information on Dosage
SCENESSE family patents
202. Sesquient patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8410077 | LUPIN | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9200088 | LUPIN | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9750822 | LUPIN | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US7635773 | LUPIN | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
Drugs and Companies using FOSPHENYTOIN SODIUM ingredient
Market Authorisation Date: 05 November, 2020
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SESQUIENT family patents
203. Seysara patent expiration
Can you believe SEYSARA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8513223 | ALMIRALL | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 01, 2023 |
Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient
NCE-1 date: 01 October, 2022
Market Authorisation Date: 01 October, 2018
Treatment: A method for treating a patient 9 years of age and older suffering from an inflammatory skin disorder of non-nodular moderate to severe acne vulgaris comprising administering an effective amount of sa...
Dosage: TABLET
More Information on Dosage
SEYSARA family patents
204. Silenor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9532971 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 17, 2013 |
Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: NA
Dosage: TABLET
How can I launch a generic of SILENOR before it's drug patent expiration?
More Information on Dosage
SILENOR family patents
205. Sirturo patent expiration
SIRTURO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546428 | JANSSEN THERAP | Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 28, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 28, 2019 |
| Orphan Drug Exclusivity(ODE-38) | Dec 28, 2019 |
| New Patient Population(NPP) | Aug 09, 2022 |
| ODE*(ODE*) | Aug 09, 2026 |
| Orphan Drug Exclusivity(ODE-251) | Aug 09, 2026 |
| Orphan Drug Exclusivity(ODE-307) | May 27, 2027 |
| M(M-306) | Jun 21, 2027 |
Drugs and Companies using BEDAQUILINE FUMARATE ingredient
NCE-1 date: 28 December, 2016
Market Authorisation Date: 27 May, 2020
Treatment: Treatment of pulmonary multi-drug resistant tuberculosis
Dosage: TABLET
More Information on Dosage
SIRTURO family patents
206. Skyclarys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9670147 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Apr, 2029
(3 years from now) | |
| US8124799 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Dec, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11919838 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Apr, 2029
(3 years from now) | |
| US11091430 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
Apr, 2029
(3 years from now) | |
| US8440854 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-270) | Dec 20, 2027 |
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2028 |
| Orphan Drug Exclusivity(ODE-427) | Feb 28, 2030 |
Drugs and Companies using OMAVELOXOLONE ingredient
NCE-1 date: 28 February, 2027
Market Authorisation Date: 28 February, 2023
Treatment: Method of treating friedrich's ataxia by activating the nrf2 pathway which reduces oxidative stress; Treatment of friedreich's ataxia in adults and adolescents aged 16 years and older
Dosage: CAPSULE
More Information on Dosage
SKYCLARYS family patents
207. Skyla patent expiration
SKYLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9615965 | BAYER HLTHCARE | Inserter |
Sep, 2029
(4 years from now) | |
| US11850182 | BAYER HLTHCARE | Inserter |
Sep, 2029
(4 years from now) | |
| US10561524 | BAYER HLTHCARE | Inserter |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 09, 2016 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 09 January, 2013
Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to rele...
Dosage: SYSTEM
More Information on Dosage
SKYLA family patents
208. Soliqua 100/33 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117909 | SANOFI-AVENTIS US | Combination of an insulin and a GLP-1 agonist |
Oct, 2029
(4 years from now) | |
| US9526764 | SANOFI-AVENTIS US | Combination of an insulin and a GLP-1-agonist |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SOLIQUA 100/33 family patents
209. Soluprep S patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623935 | 3M HEALTH CARE | Antimicrobial compositions |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 08, 2021 |
| M(M-292) | Jan 20, 2026 |
Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient
Market Authorisation Date: 08 August, 2018
Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection
Dosage: SOLUTION
More Information on Dosage
SOLUPREP S family patents
210. Sovaldi patent expiration
SOVALDI's oppositions filed in EPO
SOVALDI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(3 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
| US9549941 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(4 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(4 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
|
US9549941 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 06, 2018 |
| New Patient Population(NPP) | Apr 07, 2020 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-135) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| Orphan Drug Exclusivity(ODE-258) | Aug 28, 2026 |
Drugs and Companies using SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin
Dosage: PELLETS; TABLET
How can I launch a generic of SOVALDI before it's drug patent expiration?
More Information on Dosage
SOVALDI family patents
211. Spy Agent Green Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8406860 | NOVADAQ TECH | Method for evaluating blush in myocardial tissue |
Apr, 2029
(3 years from now) | |
| US8647605 | NOVADAQ TECH | Real time imaging during solid organ transplant |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 21, 2021 |
| New Indication(I-911) | Jun 05, 2026 |
Drugs and Companies using INDOCYANINE GREEN ingredient
Market Authorisation Date: 21 November, 2018
Treatment: Visualization of vessels, blood flow and tissue perfusion in surgical flaps in vascular, gastrointestinal, organ transplant, and plastic, micro- and reconstructive, including minimally invasive, surg...
Dosage: POWDER
How can I launch a generic of SPY AGENT GREEN KIT before it's drug patent expiration?
More Information on Dosage
SPY AGENT GREEN KIT family patents
212. Stribild patent expiration
STRIBILD's oppositions filed in EPO
STRIBILD IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148374 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9891239 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 27, 2015 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Indication(I-704) | Dec 17, 2017 |
| New Patient Population(NPP) | Jan 27, 2020 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: Treatment of hiv infection; Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET
How can I launch a generic of STRIBILD before it's drug patent expiration?
More Information on Dosage
STRIBILD family patents
213. Suboxone patent expiration
SUBOXONE's oppositions filed in EPO
SUBOXONE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9687454 | INDIVIOR | Sublingual and buccal film compositions |
Aug, 2029
(3 years from now) | |
| US11135216 | INDIVIOR | Sublingual and buccal film compositions |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 30, 2013 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 August, 2010
Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder
Dosage: FILM
How can I launch a generic of SUBOXONE before it's drug patent expiration?
More Information on Dosage
SUBOXONE family patents
214. Suprenza patent expiration
SUPRENZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440170 | CITIUS PHARMS | Orally disintegrating tablets with speckled appearance |
Mar, 2029
(3 years from now) | |
Drugs and Companies using PHENTERMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 June, 2011
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING
How can I launch a generic of SUPRENZA before it's drug patent expiration?
More Information on Dosage
SUPRENZA family patents
215. Symbicort patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8616196 | ASTRAZENECA | Inhalation device and a method for assembling said inhalation device |
Apr, 2029
(3 years from now) | |
|
US8616196 (Pediatric) | ASTRAZENECA | Inhalation device and a method for assembling said inhalation device |
Oct, 2029
(4 years from now) | |
|
US8528545 (Pediatric) | ASTRAZENECA | Inhaler device that reduces the risk for miscounting a dosage |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-582) | Feb 27, 2012 |
| New Patient Population(NPP) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| M(M-210) | Sep 11, 2020 |
| M(M-214) | Dec 20, 2020 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient
Market Authorisation Date: 21 July, 2006
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of SYMBICORT before it's drug patent expiration?
More Information on Dosage
SYMBICORT family patents
216. Symdeko (copackaged) patent expiration
SYMDEKO (COPACKAGED)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2023 |
| Orphan Drug Exclusivity(ODE-173) | Feb 12, 2025 |
| Orphan Drug Exclusivity(ODE-247) | Jun 21, 2026 |
| Orphan Drug Exclusivity(ODE-335) | Dec 21, 2027 |
Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient
NCE-1 date: 12 February, 2022
Market Authorisation Date: 21 June, 2019
Treatment: Treatment of cf in a patient age 6 years and older who is homozygous for f508del or has at least one cftr gene mutation responsive to tez/iva based on in vitro data and/or clinical evidence using the ...
Dosage: TABLET
More Information on Dosage
SYMDEKO (COPACKAGED) family patents
217. Symtuza patent expiration
SYMTUZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148374 | JANSSEN PRODS | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Combination(NC) | Jul 17, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 17 July, 2018
Treatment: Treatment of hiv-1 infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase in adults who are virologically suppressed on a stable antiretroviral...
Dosage: TABLET
How can I launch a generic of SYMTUZA before it's drug patent expiration?
More Information on Dosage
SYMTUZA family patents
218. Synjardy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Patient Population(NPP) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 26 August, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of SYNJARDY before it's drug patent expiration?
More Information on Dosage
SYNJARDY family patents
219. Synjardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-296) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 09 December, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of SYNJARDY XR before it's drug patent expiration?
More Information on Dosage
SYNJARDY XR family patents
220. Tabrecta patent expiration
TABRECTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8901123 | NOVARTIS PHARM | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 06, 2025 |
| Orphan Drug Exclusivity(ODE-291) | May 06, 2027 |
Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient
NCE-1 date: 06 May, 2024
Market Authorisation Date: 06 May, 2020
Treatment: Use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation
Dosage: TABLET
More Information on Dosage
TABRECTA family patents
221. Tafinlar patent expiration
TAFINLAR's oppositions filed in EPO
Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9233956 | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
May, 2029
(3 years from now) | |
|
US9233956 (Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Nov, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-678) | Jan 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-47) | May 29, 2020 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-58) | Jan 09, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-147) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| New Indication(I-894) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Sep 16, 2026 |
| New Indication(I-908) | Mar 16, 2026 |
| New Product(NP) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: Tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.
Dosage: CAPSULE
More Information on Dosage
TAFINLAR family patents
222. Talzenna patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8012976 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Oct, 2029
(4 years from now) | |
| US8420650 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Jul, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9820985 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Jul, 2029
(3 years from now) | |
| US10780088 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2023 |
| New Indication(I-920) | Jun 20, 2026 |
Drugs and Companies using TALAZOPARIB TOSYLATE ingredient
NCE-1 date: 16 October, 2022
Market Authorisation Date: 20 June, 2023
Treatment: Treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (brca)-mutated (gbrcam) human epidermal growth factor receptor 2 (her2)-negative locall...
Dosage: CAPSULE
More Information on Dosage
TALZENNA family patents
223. Tarpeyo patent expiration
TARPEYO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8491932 | CALLIDITAS | Compositions for the oral delivery of corticosteroids |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2024 |
| Orphan Drug Exclusivity(ODE-389) | Dec 15, 2028 |
| Orphan Drug Exclusivity(ODE-464) | Dec 20, 2030 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 15 December, 2021
Treatment: Reduction in loss of kidney function in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
TARPEYO family patents
224. Tasigna patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8163904 (Pediatric) | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2012 |
| New Indication(I-627) | Jun 17, 2014 |
| Orphan Drug Exclusivity(ODE) | Oct 29, 2014 |
| New Dosing Schedule(D-170) | Dec 22, 2020 |
| New Patient Population(NPP) | Mar 22, 2021 |
| Orphan Drug Exclusivity(ODE-171) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-172) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-380) | Sep 23, 2028 |
| Pediatric Exclusivity(PED) | Mar 23, 2029 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 23 March, 2028
Market Authorisation Date: 22 March, 2018
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of TASIGNA before it's drug patent expiration?
More Information on Dosage
TASIGNA family patents
225. Tavneos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906938 | CHEMOCENTRYX | C5aR antagonists |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 07, 2026 |
| Orphan Drug Exclusivity(ODE-377) | Oct 07, 2028 |
Drugs and Companies using AVACOPAN ingredient
NCE-1 date: 07 October, 2025
Market Authorisation Date: 07 October, 2021
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
TAVNEOS family patents
226. Technivie patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-743) | Jul 24, 2018 |
| New Product(NP) | Jul 24, 2018 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 24 July, 2015
Treatment: Treatment of hcv infection using paritaprevir
Dosage: TABLET
More Information on Dosage
TECHNIVIE family patents
227. Tekamlo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8613949 | NOVARTIS | Galenical formulations of organic compounds |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Combination(NC) | Aug 26, 2013 |
Drugs and Companies using ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE ingredient
NCE-1 date: 06 March, 2011
Market Authorisation Date: 26 August, 2010
Treatment: NA
Dosage: TABLET
More Information on Dosage
TEKAMLO family patents
228. Tepmetko patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8329692 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 03, 2026 |
| Orphan Drug Exclusivity(ODE-325) | Feb 03, 2028 |
Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 February, 2025
Market Authorisation Date: 03 February, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
TEPMETKO family patents
229. Tiglutik Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765150 | ITALFARMACO SA | Riluzole aqueous suspensions |
Mar, 2029
(3 years from now) | |
Drugs and Companies using RILUZOLE ingredient
Market Authorisation Date: 05 September, 2018
Treatment: A method of treating amyotrophic lateral sclerosis in a patient in need of such treatment, said method comprising administering to said patient an effective amount of a suspension according to claim 1
Dosage: SUSPENSION
How can I launch a generic of TIGLUTIK KIT before it's drug patent expiration?
More Information on Dosage
TIGLUTIK KIT family patents
230. Tivicay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-166) | Jul 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Indication(I-758) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 09 June, 2016
Treatment: NA
Dosage: TABLET
How can I launch a generic of TIVICAY before it's drug patent expiration?
More Information on Dosage
TIVICAY family patents
231. Tivicay Pd patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(4 years from now) | |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
Market Authorisation Date: 12 June, 2020
Treatment: NA
Dosage: TABLET, FOR SUSPENSION
How can I launch a generic of TIVICAY PD before it's drug patent expiration?
More Information on Dosage
TIVICAY PD family patents
232. Tlando patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11304960 | VERITY | Steroidal compositions |
Jan, 2029
(3 years from now) | |
| US8865695 | VERITY | Steroidal compositions |
Jan, 2029
(3 years from now) | |
| US8778922 | VERITY | Steroidal compositions |
Jan, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: CAPSULE
More Information on Dosage
TLANDO family patents
233. Tradjenta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9486526 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(3 years from now) | |
| US10034877 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-118) | Aug 13, 2015 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin; Treatment of type 2 diabetes mel...
Dosage: TABLET
How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage
TRADJENTA family patents
234. Travatan Z patent expiration
TRAVATAN Z's oppositions filed in EPO
TRAVATAN Z IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268299 | SANDOZ | Self preserved aqueous pharmaceutical compositions |
Oct, 2029
(4 years from now) | |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 21 September, 2006
Treatment: NA
Dosage: SOLUTION/DROPS
How can I launch a generic of TRAVATAN Z before it's drug patent expiration?
More Information on Dosage
TRAVATAN Z family patents
235. Treanda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8445524 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8883836 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(3 years from now) | |
| US9533955 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(3 years from now) | |
| US8344006 | CEPHALON | Liquid formulations of bendamustine |
Sep, 2029
(4 years from now) | |
| US8669279 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(3 years from now) | |
|
US8445524 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(4 years from now) | |
|
US8883836 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(4 years from now) | |
|
US8669279 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(4 years from now) | |
|
US9533955 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-580) | Oct 31, 2011 |
| New Chemical Entity Exclusivity(NCE) | Mar 20, 2013 |
| Pediatric Exclusivity(PED) | May 01, 2016 |
| Orphan Drug Exclusivity(ODE) | Oct 31, 2015 |
| ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
NCE-1 date: 02 May, 2015
Market Authorisation Date: 01 May, 2009
Treatment: For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl); For use in the treatment of patients with chronic lymphocytic leukemia (...
Dosage: POWDER; SOLUTION
How can I launch a generic of TREANDA before it's drug patent expiration?
More Information on Dosage
TREANDA family patents
236. Trelstar patent expiration
TRELSTAR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10166181 | VERITY | Slow release pharmaceutical composition made of microgranules |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 10, 2013 |
Drugs and Companies using TRIPTORELIN PAMOATE ingredient
Market Authorisation Date: 10 March, 2010
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
TRELSTAR family patents
237. Tresiba patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7615532 | NOVO | Insulin derivatives |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TRESIBA family patents
238. Triesence patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8211880 | HARROW EYE | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Mar, 2029
(3 years from now) | |
| US8128960 | HARROW EYE | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Dec, 2029
(4 years from now) | |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 29 November, 2007
Treatment: Treatment of ophthalmic disorders
Dosage: INJECTABLE
More Information on Dosage
TRIESENCE family patents
239. Triferic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7816404 | ROCKWELL MEDICAL INC | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
Apr, 2029
(3 years from now) | |
Drugs and Companies using FERRIC PYROPHOSPHATE CITRATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Method of iron administration to treat patients in need of iron replacement
Dosage: POWDER; SOLUTION
More Information on Dosage
TRIFERIC family patents
240. Triferic Avnu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7816404 | ROCKWELL MEDICAL INC | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
Apr, 2029
(3 years from now) | |
Drugs and Companies using FERRIC PYROPHOSPHATE CITRATE ingredient
Market Authorisation Date: 27 March, 2020
Treatment: Method of iron administration to treat patients in need of iron replacement therapy
Dosage: SOLUTION
More Information on Dosage
TRIFERIC AVNU family patents
241. Trijardy Xr patent expiration
TRIJARDY XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8551957 | BOEHRINGER INGELHEIM | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
Oct, 2029
(4 years from now) | |
| US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(3 years from now) | |
| US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(3 years from now) | |
|
US7579449 (Pediatric) | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Feb, 2029
(3 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: Method of treating type 2 diabetes mellitus using a pharmaceutical composition comprising empagliflozin, linagliptin and metformin; Method of treating type 2 diabetes using a pharmaceutical compositio...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage
TRIJARDY XR family patents
242. Trikafta (copackaged) patent expiration
TRIKAFTA (COPACKAGED)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 08, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
| New Product(NP) | Apr 26, 2026 |
| Orphan Drug Exclusivity(ODE-275) | Oct 21, 2026 |
| M(M-313) | Dec 20, 2027 |
| ODE*(ODE*) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-323) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-357) | Jun 08, 2028 |
| Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
| Orphan Drug Exclusivity(ODE-512) | Dec 20, 2031 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 08 June, 2021
Treatment: Treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a responsive mutation based on clinical and/or in vitro data by administering...
Dosage: TABLET; GRANULES
More Information on Dosage
TRIKAFTA (COPACKAGED) family patents
243. Triptodur Kit patent expiration
TRIPTODUR KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10166181 | AZURITY | Slow release pharmaceutical composition made of microgranules |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 29, 2020 |
| Orphan Drug Exclusivity(ODE) | Jun 29, 2024 |
| Orphan Drug Exclusivity(ODE-149) | Jun 29, 2024 |
Drugs and Companies using TRIPTORELIN PAMOATE ingredient
Market Authorisation Date: 29 June, 2017
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
TRIPTODUR KIT family patents
244. Triumeq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-147) | Mar 23, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| M(M-294) | Jun 15, 2026 |
| Pediatric Exclusivity(PED) | Dec 15, 2026 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
NCE-1 date: 15 December, 2025
Market Authorisation Date: 22 August, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of TRIUMEQ before it's drug patent expiration?
More Information on Dosage
TRIUMEQ family patents
245. Triumeq Pd patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 15, 2026 |
| Pediatric Exclusivity(PED) | Dec 15, 2026 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 30 March, 2022
Treatment: NA
Dosage: TABLET, FOR SUSPENSION
How can I launch a generic of TRIUMEQ PD before it's drug patent expiration?
More Information on Dosage
TRIUMEQ PD family patents
246. Truseltiq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8552002 | HELSINN HLTHCARE | Compounds and compositions as protein kinase inhibitors |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-353) | May 28, 2028 |
Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
TRUSELTIQ family patents
247. Tryvio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324232 | IDORSIA | 4-pyrimidinesulfamide derivative |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2029 |
Drugs and Companies using APROCITENTAN ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 19 March, 2024
Treatment: Treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs
Dosage: TABLET
More Information on Dosage
TRYVIO family patents
248. Tudorza Pressair patent expiration
TUDORZA PRESSAIR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10085974 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
| US11000517 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2017 |
| M(M-256) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE ingredient
NCE-1 date: 23 July, 2016
Market Authorisation Date: 23 July, 2012
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)
Dosage: POWDER, METERED
More Information on Dosage
TUDORZA PRESSAIR family patents
249. Tuzistra Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8062667 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(3 years from now) | |
Drugs and Companies using CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX ingredient
Market Authorisation Date: 30 April, 2015
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
TUZISTRA XR family patents
250. Tybost patent expiration
TYBOST's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148374 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Product(NP) | Sep 24, 2017 |
| New Patient Population(NPP) | Aug 22, 2022 |
| Orphan Drug Exclusivity(ODE-260) | Aug 22, 2026 |
Drugs and Companies using COBICISTAT ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 20 June, 2025
Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET
How can I launch a generic of TYBOST before it's drug patent expiration?
More Information on Dosage
TYBOST family patents
251. Tygacil patent expiration
TYGACIL's oppositions filed in EPO
TYGACIL IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7879828 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-586) | Mar 20, 2012 |
| New Indication(I-587) | Mar 20, 2012 |
| New Indication(I-588) | Mar 20, 2012 |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Treatment: NA
Dosage: POWDER
More Information on Dosage
TYGACIL family patents
252. Tykerb patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8821927 | NOVARTIS | Pharmaceutical composition |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2012 |
| New Indication(I-620) | Jan 29, 2013 |
| M(M-235) | Dec 06, 2021 |
Drugs and Companies using LAPATINIB DITOSYLATE ingredient
NCE-1 date: 14 March, 2011
Market Authorisation Date: 13 March, 2007
Treatment: NA
Dosage: TABLET
How can I launch a generic of TYKERB before it's drug patent expiration?
More Information on Dosage
TYKERB family patents
253. Uptravi patent expiration
UPTRAVI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173881 | ACTELION | Therapeutic compositions containing macitentan |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2022 |
| Orphan Drug Exclusivity(ODE-106) | Dec 21, 2022 |
Drugs and Companies using SELEXIPAG ingredient
NCE-1 date: 22 December, 2019
Market Authorisation Date: 21 December, 2015
Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan
Dosage: TABLET; POWDER
How can I launch a generic of UPTRAVI before it's drug patent expiration?
More Information on Dosage
UPTRAVI family patents
254. Valchlor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7872050 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 23, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 23, 2020 |
| Orphan Drug Exclusivity(ODE-51) | Aug 23, 2020 |
Drugs and Companies using MECHLORETHAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy
Dosage: GEL
More Information on Dosage
VALCHLOR family patents
255. Valtoco patent expiration
VALTOCO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9763876 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(3 years from now) | |
| US11241414 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(3 years from now) | |
| US12268664 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(3 years from now) | |
| US11793786 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(3 years from now) | |
| US8895546 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 10, 2023 |
| Orphan Drug Exclusivity(ODE-279) | Jan 10, 2027 |
| New Patient Population(NPP) | Apr 15, 2028 |
Drugs and Companies using DIAZEPAM ingredient
Market Authorisation Date: 10 January, 2020
Treatment: Nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older
Dosage: SPRAY
More Information on Dosage
VALTOCO family patents
256. Vanflyta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7968543 | DAIICHI SANKYO INC | Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
Aug, 2029
(3 years from now) | |
| US8865710 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
| Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...
Dosage: TABLET
More Information on Dosage
VANFLYTA family patents
257. Vantrela Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8445018 | TEVA BRANDED PHARM | Abuse resistant drug formulation |
Jul, 2029
(3 years from now) | |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 17 January, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
VANTRELA ER family patents
258. Varubi patent expiration
VARUBI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470842 | TERSERA | Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
Jan, 2029
(3 years from now) | |
| US8361500 | TERSERA | Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 01, 2020 |
Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient
NCE-1 date: 02 September, 2019
Market Authorisation Date: 01 September, 2015
Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy
Dosage: TABLET; EMULSION
More Information on Dosage
VARUBI family patents
259. Veklury patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8318682 | GILEAD SCIENCES INC | 1′substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(3 years from now) | |
| US8008264 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Sep, 2029
(3 years from now) | |
| USRE46762 | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Apr, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8318682 (Pediatric) | GILEAD SCIENCES INC | 1′substituted carba-nucleoside analogs for antiviral treatment |
Oct, 2029
(4 years from now) | |
|
USRE46762 (Pediatric) | GILEAD SCIENCES INC | 1′-substituted carba-nucleoside analogs for antiviral treatment |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-183) | Jan 21, 2025 |
| New Patient Population(NPP) | Apr 25, 2025 |
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
| M(M-301) | Jul 13, 2026 |
| Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 13 January, 2026
Market Authorisation Date: 22 October, 2020
Treatment: NA
Dosage: POWDER; SOLUTION
More Information on Dosage
VEKLURY family patents
260. Velphoro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11013762 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(3 years from now) | |
|
US10925896 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(3 years from now) | |
|
US10925897 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(3 years from now) | |
|
US10933090 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(3 years from now) | |
|
US10682376 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(3 years from now) | |
|
US11013761 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(3 years from now) | |
|
US10695367 (Pediatric) | VIFOR FRESENIUS | Pharmaceutical compositions |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 27, 2016 |
| New Patient Population(NPP) | Jul 01, 2027 |
| Pediatric Exclusivity(PED) | Jan 01, 2028 |
Drugs and Companies using FERRIC OXYHYDROXIDE ingredient
Market Authorisation Date: 27 November, 2013
Treatment: NA
Dosage: TABLET, CHEWABLE
More Information on Dosage
VELPHORO family patents
261. Velsipity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9126932 | PFIZER | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2028 |
Drugs and Companies using ETRASIMOD ARGININE ingredient
NCE-1 date: 13 October, 2027
Market Authorisation Date: 12 October, 2023
Treatment: A method for treating ulcerative colitis by administering a therapeutically effective amount of estrasimod arginine
Dosage: TABLET
More Information on Dosage
VELSIPITY family patents
262. Verkazia patent expiration
Can you believe VERKAZIA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132071 | HARROW EYE | Compositions containing quaternary ammonium compounds |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 23, 2024 |
| Orphan Drug Exclusivity(ODE-358) | Jun 23, 2028 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 June, 2021
Treatment: NA
Dosage: EMULSION
More Information on Dosage
VERKAZIA family patents
263. Viberzi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7741356 | ABBVIE | Compounds as opioid receptor modulators |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2020 |
Drugs and Companies using ELUXADOLINE ingredient
NCE-1 date: 28 May, 2019
Market Authorisation Date: 27 May, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of VIBERZI before it's drug patent expiration?
More Information on Dosage
VIBERZI family patents
264. Viekira Pak (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(4 years from now) | |
| US8188104 | ABBVIE | Anti-infective agents and uses thereof |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-163) | Apr 22, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hcv infection using paritaprevir; Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.
Dosage: TABLET
More Information on Dosage
VIEKIRA PAK (COPACKAGED) family patents
265. Viekira Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(4 years from now) | |
| US8188104 | ABBVIE | Anti-infective agents and uses thereof |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using paritaprevir; Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
VIEKIRA XR family patents
266. Vijoice patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| Orphan Drug Exclusivity(ODE-396) | Apr 05, 2029 |
Drugs and Companies using ALPELISIB ingredient
Market Authorisation Date: 24 April, 2024
Treatment: NA
Dosage: GRANULES; TABLET
More Information on Dosage
VIJOICE family patents
267. Vimovo patent expiration
VIMOVO's oppositions filed in EPO
VIMOVO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9393208 | HORIZON | Method for delivering a pharmaceutical composition to patient in need thereof |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 30, 2013 |
| New Patient Population(NPP) | Jul 06, 2020 |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient
Market Authorisation Date: 30 April, 2010
Treatment: Risk-reduction of nsaid-associated gastric ulcer in patients requiring nsaid treatment
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of VIMOVO before it's drug patent expiration?
More Information on Dosage
VIMOVO family patents
268. Viramune Xr patent expiration
VIRAMUNE XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8460704 | BOEHRINGER INGELHEIM | Extended release formulation of nevirapine |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Mar 25, 2014 |
| New Patient Population(NPP) | Nov 08, 2015 |
Drugs and Companies using NEVIRAPINE ingredient
Market Authorisation Date: 08 November, 2012
Treatment: Treatment of hiv-1 by once daily administration
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of VIRAMUNE XR before it's drug patent expiration?
More Information on Dosage
VIRAMUNE XR family patents
269. Vitrakvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8513263 | BAYER HLTHCARE | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
Dec, 2029
(4 years from now) | |
| US9127013 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10005783 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| US10047097 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| US10774085 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| US9447104 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| US8865698 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| US9676783 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 26, 2023 |
| Orphan Drug Exclusivity(ODE-215) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-220) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-221) | Nov 26, 2025 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 26 November, 2022
Market Authorisation Date: 26 November, 2018
Treatment: Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion after surgical rese...
Dosage: CAPSULE
More Information on Dosage
VITRAKVI family patents
270. Vitrakvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8513263 | BAYER HEALTHCARE | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
Dec, 2029
(4 years from now) | |
| US9127013 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10047097 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| US8865698 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| US10005783 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| US9447104 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| US9676783 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| US10774085 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 26, 2023 |
| Orphan Drug Exclusivity(ODE-215) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-220) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-221) | Nov 26, 2025 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 26 November, 2022
Market Authorisation Date: 26 November, 2018
Treatment: Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating cancerous solid tumors; Method of treating neuroblastoma, glioma, thyroid, and breast canc...
Dosage: SOLUTION
More Information on Dosage
VITRAKVI family patents
271. Vivitrol patent expiration
VIVITROL IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7919499 | ALKERMES | Naltrexone long acting formulations and methods of use |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-631) | Oct 12, 2013 |
Drugs and Companies using NALTREXONE ingredient
Market Authorisation Date: 13 April, 2006
Treatment: Treatment of alcohol dependence
Dosage: FOR SUSPENSION, EXTENDED RELEASE
How can I launch a generic of VIVITROL before it's drug patent expiration?
More Information on Dosage
VIVITROL family patents
272. Vonjo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8153632 | SOBI | Oxygen linked pyrimidine derivatives |
Jan, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2027 |
| Orphan Drug Exclusivity(ODE-397) | Feb 28, 2029 |
Drugs and Companies using PACRITINIB CITRATE ingredient
NCE-1 date: 28 February, 2026
Market Authorisation Date: 28 February, 2022
Treatment: Treatment of myelofibrosis with pacritinib
Dosage: CAPSULE
More Information on Dosage
VONJO family patents
273. Vosevi patent expiration
VOSEVI's oppositions filed in EPO
VOSEVI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(3 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(3 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(4 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(4 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 18 July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor; Treatme...
Dosage: TABLET
More Information on Dosage
VOSEVI family patents
274. Vraylar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7737142 | ABBVIE | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE49110 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| USRE49302 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| USRE47350 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 17, 2020 |
| M(M-213) | Nov 09, 2020 |
| New Indication(I-798) | May 24, 2022 |
| New Indication(I-904) | Dec 16, 2025 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
NCE-1 date: 18 September, 2019
Market Authorisation Date: 17 September, 2015
Treatment: Adjunctive therapy to antidepressants for the treatment of major depressive disorder; Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine; Treatme...
Dosage: CAPSULE
How can I launch a generic of VRAYLAR before it's drug patent expiration?
More Information on Dosage
VRAYLAR family patents
275. Vykat Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7799777 | SOLENO THERAP | Salts of potassium ATP channel openers and uses thereof |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 26, 2028 |
Drugs and Companies using DIAZOXIDE CHOLINE ingredient
Market Authorisation Date: 26 March, 2025
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
VYKAT XR family patents
276. Vyxeos patent expiration
VYXEOS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8092828 | CELATOR PHARMS | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 03, 2020 |
| New Patient Population(NPP) | Mar 30, 2024 |
| Orphan Drug Exclusivity(ODE-287) | Aug 03, 2024 |
| Orphan Drug Exclusivity(ODE-350) | Mar 30, 2028 |
Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient
Market Authorisation Date: 03 August, 2017
Treatment: For the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older
Dosage: POWDER
More Information on Dosage
VYXEOS family patents
277. Vyzulta patent expiration
VYZULTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8058467 | BAUSCH AND LOMB | Prostaglandin derivatives |
Feb, 2029
(3 years from now) | |
Drugs and Companies using LATANOPROSTENE BUNOD ingredient
Market Authorisation Date: 02 November, 2017
Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS
How can I launch a generic of VYZULTA before it's drug patent expiration?
More Information on Dosage
VYZULTA family patents
278. Wakix patent expiration
WAKIX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8486947 | HARMONY | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands |
Sep, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-846) | Oct 13, 2023 |
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2024 |
| Orphan Drug Exclusivity(ODE-255) | Aug 14, 2026 |
| New Patient Population(NPP) | Jun 21, 2027 |
| Orphan Drug Exclusivity(ODE-331) | Oct 13, 2027 |
| Orphan Drug Exclusivity(ODE-489) | Jun 21, 2031 |
Drugs and Companies using PITOLISANT HYDROCHLORIDE ingredient
NCE-1 date: 15 August, 2023
Market Authorisation Date: 14 August, 2019
Treatment: Method of treating cataplexy in patients with narcolepsy
Dosage: TABLET
More Information on Dosage
WAKIX family patents
279. Winlevi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9433628 | SUN PHARM | Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 26, 2025 |
Drugs and Companies using CLASCOTERONE ingredient
NCE-1 date: 26 August, 2024
Market Authorisation Date: 26 August, 2020
Treatment: NA
Dosage: CREAM
More Information on Dosage
WINLEVI family patents
280. Xalkori patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7858643 | PF PRISM CV | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Oct, 2029
(4 years from now) | |
| US8217057 | PF PRISM CV | Polymorphs of a c-MET/HGFR inhibitor |
Nov, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 26, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 26, 2018 |
| Orphan Drug Exclusivity(ODE-15) | Aug 26, 2018 |
| M(M-163) | Sep 14, 2018 |
| Orphan Drug Exclusivity(ODE-111) | Mar 11, 2023 |
| New Indication(I-852) | Jan 14, 2024 |
| New Indication(I-897) | Jul 14, 2025 |
| Orphan Drug Exclusivity(ODE-328) | Jan 14, 2028 |
| Orphan Drug Exclusivity(ODE-407) | Jul 14, 2029 |
Drugs and Companies using CRIZOTINIB ingredient
NCE-1 date: 27 August, 2015
Market Authorisation Date: 26 August, 2011
Treatment: NA
Dosage: CAPSULE; CAPSULE, PELLETS
More Information on Dosage
XALKORI family patents
281. Xaracoll patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47826 | INNOCOLL PHARMS | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 28, 2023 |
Drugs and Companies using BUPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 August, 2020
Treatment: A method for inducing a post-surgical analgesia sparing effect by implanting at the surgical site a collagen sponge containing bupivacaine hcl which provides local anesthesia for up to 24 hours follow...
Dosage: IMPLANT
More Information on Dosage
XARACOLL family patents
282. Xartemis Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377453 | MALLINCKRODT INC | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
Nov, 2029
(4 years from now) | |
| US8668929 | MALLINCKRODT INC | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
Mar, 2029
(3 years from now) | |
| US8372432 | MALLINCKRODT INC | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
Mar, 2029
(3 years from now) | |
| US8394408 | MALLINCKRODT INC | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 11, 2017 |
Drugs and Companies using ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2014
Treatment: Management of acute pain in patients requiring opioid analgesia
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
XARTEMIS XR family patents
283. Xelpros patent expiration
XELPROS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629852 | SUN PHARM | Ophthalmic composition comprising a prostaglandin |
Sep, 2029
(4 years from now) | |
Drugs and Companies using LATANOPROST ingredient
Market Authorisation Date: 12 September, 2018
Treatment: NA
Dosage: EMULSION
More Information on Dosage
XELPROS family patents
284. Xepi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399014 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2022 |
Drugs and Companies using OZENOXACIN ingredient
NCE-1 date: 11 December, 2021
Market Authorisation Date: 11 December, 2017
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: CREAM
More Information on Dosage
XEPI family patents
285. Xerava patent expiration
XERAVA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796245 | TETRAPHASE PHARMS | C7-fluoro substituted tetracycline compounds |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 27, 2028 |
Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient
NCE-1 date: 28 August, 2027
Market Authorisation Date: 27 August, 2018
Treatment: Treatment of complicated intra-abdominal infections in patients 18 years of age and older
Dosage: POWDER
More Information on Dosage
XERAVA family patents
286. Xhance patent expiration
XHANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10076615 | OPTINOSE US INC | Nasal delivery |
Jul, 2029
(3 years from now) | |
| US8550073 | OPTINOSE US INC | Nasal delivery |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 18, 2020 |
| New Indication(I-940) | Mar 15, 2027 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: Method of delivering fluticasone propionate to a nasal airway
Dosage: SPRAY, METERED
More Information on Dosage
XHANCE family patents
287. Xifaxan patent expiration
XIFAXAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456384 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US10335397 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US9421195 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US8946252 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US8829017 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US8642573 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(4 years from now) | |
| US10314828 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US10709694 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US10765667 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US8969398 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(4 years from now) | |
| US9629828 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US8309569 | SALIX PHARMS | Methods for treating diarrhea-associated irritable bowel syndrome |
Jul, 2029
(3 years from now) | |
| US7928115 | SALIX PHARMS | Methods of treating travelers diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US11779571 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US11564912 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 24, 2013 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
| New Indication(I-709) | May 27, 2018 |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 24 March, 2010
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode; ...
Dosage: TABLET
How can I launch a generic of XIFAXAN before it's drug patent expiration?
More Information on Dosage
XIFAXAN family patents
288. Xigduo Xr patent expiration
XIGDUO XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 28 July, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of XIGDUO XR before it's drug patent expiration?
More Information on Dosage
XIGDUO XR family patents
289. Xiidra patent expiration
Can you believe XIIDRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8367701 | BAUSCH AND LOMB INC | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(3 years from now) | |
| US8168655 | BAUSCH AND LOMB INC | Compositions and methods for treatment of eye disorders |
May, 2029
(3 years from now) | |
| US9447077 | BAUSCH AND LOMB INC | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Treatment: Treatment of signs and symptoms of dry eye disease (ded); Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS
How can I launch a generic of XIIDRA before it's drug patent expiration?
More Information on Dosage
XIIDRA family patents
290. Xphozah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8969377 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(4 years from now) | |
| US12016856 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
| New Product(NP) | Oct 17, 2026 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 17 October, 2023
Treatment: NA
Dosage: TABLET
More Information on Dosage
XPHOZAH family patents
291. Xultophy 100/3.6 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7615532 | NOVO | Insulin derivatives |
Jun, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8937042 (Pediatric) | NOVO | Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide |
Nov, 2029
(4 years from now) | |
|
US7615532 (Pediatric) | NOVO | Insulin derivatives |
Dec, 2029
(4 years from now) | |
| US8937042 | NOVO | Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
| M(M-242) | Aug 08, 2022 |
Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XULTOPHY 100/3.6 family patents
292. Zecuity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8366600 | TEVA BRANDED PHARM | Polyamine enhanced formulations for triptan compound iontophoresis |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 17, 2016 |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 17 January, 2013
Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof, using a flowable hydrogel formulation
Dosage: SYSTEM
More Information on Dosage
ZECUITY family patents
293. Zejula patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8436185 | GLAXOSMITHKLINE | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2022 |
| New Indication(I-813) | Oct 23, 2022 |
| New Indication(I-814) | Oct 23, 2022 |
| New Indication(I-833) | Apr 29, 2023 |
| Orphan Drug Exclusivity(ODE) | Mar 27, 2024 |
| Orphan Drug Exclusivity(ODE-133) | Mar 27, 2024 |
| Orphan Drug Exclusivity(ODE-277) | Oct 23, 2026 |
| Orphan Drug Exclusivity(ODE-278) | Oct 23, 2026 |
| Orphan Drug Exclusivity(ODE-295) | Apr 29, 2027 |
Drugs and Companies using NIRAPARIB TOSYLATE ingredient
NCE-1 date: 27 March, 2021
Market Authorisation Date: 27 March, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
ZEJULA family patents
294. Zelboraf patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7863288 | HOFFMANN LA ROCHE | NA |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 17, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 17, 2018 |
| Orphan Drug Exclusivity(ODE-13) | Aug 17, 2018 |
| M(M-184) | Aug 31, 2019 |
| New Indication(I-757) | Nov 06, 2020 |
| Orphan Drug Exclusivity(ODE-158) | Nov 06, 2024 |
Drugs and Companies using VEMURAFENIB ingredient
NCE-1 date: 18 August, 2015
Market Authorisation Date: 17 August, 2011
Treatment: NA
Dosage: TABLET
More Information on Dosage
ZELBORAF family patents
295. Zepatier patent expiration
Can you believe ZEPATIER received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7973040 | MSD SUB MERCK | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 28, 2021 |
| New Patient Population(NPP) | Dec 09, 2024 |
Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient
NCE-1 date: 29 January, 2020
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of patients infected with hepatitis c virus
Dosage: TABLET
More Information on Dosage
ZEPATIER family patents
296. Zeposia patent expiration
Can you believe ZEPOSIA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8796318 | BRISTOL | Modulators of sphingosine phosphate receptors |
May, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9382217 | BRISTOL | Modulators of sphingosine phosphate receptors |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-860) | May 27, 2024 |
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2025 |
| M(M-309) | Aug 30, 2027 |
Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient
NCE-1 date: 25 March, 2024
Market Authorisation Date: 25 March, 2020
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Dosage: CAPSULE
More Information on Dosage
ZEPOSIA family patents
297. Zepzelca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7763615 | JAZZ | Ecteinascidin analogs for use as antitumour agents |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2025 |
| Orphan Drug Exclusivity(ODE-304) | Jun 15, 2027 |
Drugs and Companies using LURBINECTEDIN ingredient
NCE-1 date: 15 June, 2024
Market Authorisation Date: 15 June, 2020
Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.
Dosage: POWDER
More Information on Dosage
ZEPZELCA family patents
298. Zingo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8540665 | POWDER PHARMS | Particle cassettes and processes therefor |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jan 08, 2012 |
Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 August, 2007
Treatment: Zingo intradermal injection system is a drug delivery system that is capable of delivering fine dry powdered lidocaine hydrochloride monohydrate for local anesthetic action
Dosage: SYSTEM
More Information on Dosage
ZINGO family patents
299. Zioptan patent expiration
ZIOPTAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10864159 | THEA PHARMA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(3 years from now) | |
| US9999593 | THEA PHARMA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 10, 2017 |
Drugs and Companies using TAFLUPROST ingredient
NCE-1 date: 11 February, 2016
Market Authorisation Date: 10 February, 2012
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS
How can I launch a generic of ZIOPTAN before it's drug patent expiration?
More Information on Dosage
ZIOPTAN family patents
300. Zipsor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7884095 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(3 years from now) | |
| US8110606 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(3 years from now) | |
| US8623920 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(3 years from now) | |
| US9561200 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(3 years from now) | |
| US7662858 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(3 years from now) | |
| US7939518 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 16, 2012 |
| New Patient Population(NPP) | May 25, 2024 |
Drugs and Companies using DICLOFENAC POTASSIUM ingredient
Market Authorisation Date: 16 June, 2009
Treatment: Nonsteroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain; Diclofenac potassium for relief of mild to moderate acute pain
Dosage: CAPSULE
How can I launch a generic of ZIPSOR before it's drug patent expiration?
More Information on Dosage
ZIPSOR family patents
301. Zokinvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7838531 | SENTYNL THERAPS INC | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2025 |
| Orphan Drug Exclusivity(ODE-324) | Nov 20, 2027 |
Drugs and Companies using LONAFARNIB ingredient
NCE-1 date: 20 November, 2024
Market Authorisation Date: 20 November, 2020
Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)
Dosage: CAPSULE
More Information on Dosage
ZOKINVY family patents
302. Zulresso patent expiration
Can you believe ZULRESSO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750822 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9200088 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US7635773 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US10117951 | SAGE THERAP | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| New Patient Population(NPP) | Jun 16, 2025 |
Drugs and Companies using BREXANOLONE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ZULRESSO family patents
303. Zuplenz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8580830 | AQUESTIVE | Non-mucoadhesive film dosage forms |
Nov, 2029
(4 years from now) | |
Drugs and Companies using ONDANSETRON ingredient
Market Authorisation Date: 02 July, 2010
Treatment: NA
Dosage: FILM
More Information on Dosage
ZUPLENZ family patents
304. Zuragard patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8389583 | ZUREX PHARMA | Antimicrobial compositions and methods of use |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 26, 2022 |
| M(M-268) | Jun 24, 2024 |
Drugs and Companies using ISOPROPYL ALCOHOL ingredient
Market Authorisation Date: 26 April, 2019
Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery
Dosage: SOLUTION
More Information on Dosage
ZURAGARD family patents
305. Zurampic patent expiration
Can you believe ZURAMPIC received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8084483 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Aug, 2029
(3 years from now) | |
| US8357713 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Dec, 2029
(4 years from now) | |
| US8546437 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2020 |
Drugs and Companies using LESINURAD ingredient
NCE-1 date: 23 December, 2019
Market Authorisation Date: 22 December, 2015
Treatment: Reduction of serum uric acid levels; Treatment of gout; Treatment of hyperuricemia
Dosage: TABLET
More Information on Dosage
ZURAMPIC family patents
306. Zyclara patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236816 | BAUSCH | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod |
Dec, 2029
(4 years from now) | |
| US11318130 | BAUSCH | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(4 years from now) | |
| US10238645 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Aug, 2029
(3 years from now) | |
| US8299109 | BAUSCH | Method of treating actinic keratosis with 3.75% imiquimod cream |
Dec, 2029
(4 years from now) | |
| US10238644 | BAUSCH | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(4 years from now) | |
| US8598196 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Aug, 2029
(3 years from now) | |
| US8222270 | BAUSCH | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod |
Dec, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 25, 2013 |
| New Indication(I-636) | Mar 24, 2014 |
| New Strength(NS) | Jul 15, 2014 |
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 15 July, 2011
Treatment: Treatment of actinic keratosis; Treatment of perianal warts
Dosage: CREAM
How can I launch a generic of ZYCLARA before it's drug patent expiration?
More Information on Dosage
ZYCLARA family patents